{"protocolSection":{"identificationModule":{"nctId":"NCT03766581","orgStudyIdInfo":{"id":"CV010-031"},"organization":{"fullName":"Bristol-Myers Squibb","class":"INDUSTRY"},"briefTitle":"A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel","officialTitle":"A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)","acronym":"AXIOMATIC-SSP"},"statusModule":{"statusVerifiedDate":"2023-06","overallStatus":"COMPLETED","startDateStruct":{"date":"2019-01-27","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-03-31","type":"ACTUAL"},"completionDateStruct":{"date":"2022-03-31","type":"ACTUAL"},"studyFirstSubmitDate":"2018-11-13","studyFirstSubmitQcDate":"2018-12-05","studyFirstPostDateStruct":{"date":"2018-12-06","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-03-31","resultsFirstSubmitQcDate":"2023-06-08","resultsFirstPostDateStruct":{"date":"2023-06-12","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-06-08","lastUpdatePostDateStruct":{"date":"2023-06-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bristol-Myers Squibb","class":"INDUSTRY"},"collaborators":[{"name":"Janssen, LP","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention."},"conditionsModule":{"conditions":["Acute Ischemic Stroke","Transient Ischemic Attack (TIA)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":2366,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"BMS-986177 Placebo","type":"PLACEBO_COMPARATOR","description":"Specified Dose on Specified Days","interventionNames":["Other: Placebo","Drug: Clopidogrel","Drug: Aspirin"]},{"label":"Dose 1: BMS-986177 + Aspirin + Clopidogrel","type":"EXPERIMENTAL","description":"Specified Dose on Specified Days","interventionNames":["Drug: BMS-986177","Drug: Clopidogrel","Drug: Aspirin"]},{"label":"Dose 2: BMS-986177 + Aspirin + Clopidogrel","type":"EXPERIMENTAL","description":"Specified Dose on Specified Days","interventionNames":["Drug: BMS-986177","Drug: Clopidogrel","Drug: Aspirin"]},{"label":"Dose 3: BMS-986177 + Aspirin + Clopidogrel","type":"EXPERIMENTAL","description":"Specified Dose on Specified Days","interventionNames":["Drug: BMS-986177","Drug: Clopidogrel","Drug: Aspirin"]},{"label":"Dose 4: BMS-986177 + Aspirin + Clopidogrel","type":"EXPERIMENTAL","description":"Specified Dose on Specified Days","interventionNames":["Drug: BMS-986177","Drug: Clopidogrel","Drug: Aspirin"]},{"label":"Dose 5: BMS-986177 + Aspirin + Clopidogrel","type":"EXPERIMENTAL","description":"Specified Dose on Specified Days","interventionNames":["Drug: BMS-986177","Drug: Clopidogrel","Drug: Aspirin"]},{"label":"Dose 6: BMS-986177 + Aspirin + Clopidogrel","type":"EXPERIMENTAL","description":"Specified Dose on Specified Days","interventionNames":["Drug: BMS-986177","Drug: Clopidogrel","Drug: Aspirin"]},{"label":"Dose 7: BMS-986177 + Aspirin + Clopidogrel","type":"EXPERIMENTAL","description":"Specified Dose on Specified Days","interventionNames":["Drug: BMS-986177","Drug: Clopidogrel","Drug: Aspirin"]}],"interventions":[{"type":"DRUG","name":"BMS-986177","description":"Oral administration","armGroupLabels":["Dose 1: BMS-986177 + Aspirin + Clopidogrel","Dose 2: BMS-986177 + Aspirin + Clopidogrel","Dose 3: BMS-986177 + Aspirin + Clopidogrel","Dose 4: BMS-986177 + Aspirin + Clopidogrel","Dose 5: BMS-986177 + Aspirin + Clopidogrel","Dose 6: BMS-986177 + Aspirin + Clopidogrel","Dose 7: BMS-986177 + Aspirin + Clopidogrel"]},{"type":"OTHER","name":"Placebo","description":"Oral Administration","armGroupLabels":["BMS-986177 Placebo"]},{"type":"DRUG","name":"Clopidogrel","description":"Oral administration","armGroupLabels":["BMS-986177 Placebo","Dose 1: BMS-986177 + Aspirin + Clopidogrel","Dose 2: BMS-986177 + Aspirin + Clopidogrel","Dose 3: BMS-986177 + Aspirin + Clopidogrel","Dose 4: BMS-986177 + Aspirin + Clopidogrel","Dose 5: BMS-986177 + Aspirin + Clopidogrel","Dose 6: BMS-986177 + Aspirin + Clopidogrel","Dose 7: BMS-986177 + Aspirin + Clopidogrel"]},{"type":"DRUG","name":"Aspirin","description":"Oral administration","armGroupLabels":["BMS-986177 Placebo","Dose 1: BMS-986177 + Aspirin + Clopidogrel","Dose 2: BMS-986177 + Aspirin + Clopidogrel","Dose 3: BMS-986177 + Aspirin + Clopidogrel","Dose 4: BMS-986177 + Aspirin + Clopidogrel","Dose 5: BMS-986177 + Aspirin + Clopidogrel","Dose 6: BMS-986177 + Aspirin + Clopidogrel","Dose 7: BMS-986177 + Aspirin + Clopidogrel"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90","description":"Model based assessment estimate for composite event is a customized statistical analysis called MCP-MOD (Multiple Comparison Procedures, MODel) estimation, which is used to check for dose-response relationship. 95% confidence interval (CI) for composite event based on bootstrap (10000 samples).","timeFrame":"From randomization to up to 90 days after randomization"}],"secondaryOutcomes":[{"measure":"Percent of Participants With Major Bleeding According to BARC Type 3 and 5","description":"Percent of participants with major bleeding based on the Bleeding Academic Research Consortium (BARC) Types 3 and 5 definitions. BARC bleeding types:\n\n3a = Overt bleeding plus hemoglobin drop of 3 to \\< 5 g/dL transfusion with overt bleeding 3b = Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents 3c = Intracranial hemorrhage, 5a = Probable fatal bleeding 5b = Definite fatal bleeding","timeFrame":"From first dose to up to 107 days after first dose"},{"measure":"Number of Participants With Bleeding Based on BARC Types 1-5","description":"Number of participants with bleeding based on Bleeding Academic Research Consortium (BARC) Type 1 to 5. BARC bleeding types: 0=No bleeding. 1=Not actionable bleeding. 2=Overt, actionable sign of hemorrhage requiring nonsurgical, medical intervention by a health-care professional, leading to hospitalization or increased level of care, or prompting evaluation. 3a=Overt bleeding plus hemoglobin drop of 3 to \\< 5 g/dL. 3b=Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention; bleeding requiring IV vasoactive agents. 3c=Intracranial hemorrhage; intraocular bleed compromising vision. 4=CABG-related bleeding, perioperative intracranial bleeding within 48 hours, reoperation after closure of sternotomy to control bleeding, transfusion of ≥5 U whole blood or packed red blood cells within a 48-hour period, chest tube output more than or equal to 2L within a 24-hour period. 5a=Probable fatal bleeding. 5b=Definite fatal bleeding.","timeFrame":"From first dose to up to 107 days after first dose"},{"measure":"Number of Participants With Bleeding Based on ISTH-Defined Criteria","description":"Number of participants with bleeding based on International Society on Thrombosis and Hemostasis (ISTH). ISTH Bleeding Types: 1) Fatal bleeding and/or 2) Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome and/or 3) Bleeding causing a fall in hemoglobin level of ≥2 g/dL, or leading to transfusion of ≥2 units of whole blood or red cells.","timeFrame":"From first dose to up to 107 days after first dose"},{"measure":"Number of Participants With Bleeding Based on PLATO-Defined Criteria","description":"Number of participants with bleeding based on Platelet Inhibition and Patient Outcomes (PLATO) defined criteria. PLATO bleeding definitions:\n\n1. Major Life-threatening: Fatal, Intracranial, Intrapericardial with cardiac tamponade, Resulting in hypovolemic shock or severe hypotension that requires pressors or surgery, Clinically overt or apparent bleeding associated with decrease in hemoglobin \\>5 g/dL, Requiring transfusion of ≥4 U whole blood or packed red blood cells (PRBCs)\n2. Other Major: Significantly disabling (eg, intraocular with permanent vision loss), Associated drop in hemoglobin of 3 to 5 g/dL, Requiring transfusion of 2 to 3 U whole blood or PRBCs\n3. Any Major: Any one of the above criteria\n4. Minor: Bleeding that does not meet criteria for PLATO Major bleeding, and requiring medical intervention","timeFrame":"From first dose to up to 107 days after first dose"},{"measure":"Percent of Participants With Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90","description":"Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90.","timeFrame":"From randomization to up to 90 days after randomization"},{"measure":"Composite of Percent of Participants With New Ischemic Stroke, MI and All Cause Death","description":"Composite of percent of participants of new ischemic stroke, (Myocardial Infarction) MI and all cause death.","timeFrame":"From randomization to up to 90 days after randomization"},{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"The NIHSS is an 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. The score for each ability is a number between 0 and 4, 0 being normal functioning and 4 being completely impaired. The patient's NIHSS score is calculated by adding the number for each element of the scale; 42 is the highest score possible. In the NIHSS, the higher the score, the more impaired a stroke participant is.","timeFrame":"At baseline, on Days 21 and 90, and at the time of a new stroke event"},{"measure":"Modified Rankin Scale (mRS)","description":"The Modified Rankin Score (mRS) is a 6-point disability scale with possible scores ranging from 0 to 6.\n\n0 = No symptoms at all\n\n1. = No significant disability despite symptoms; able to carry out all usual duties and activities\n2. = Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance\n3. = Moderate disability; requiring some help, but able to walk without assistance\n4. = Moderately severe disability; unable to walk and attend to bodily needs without assistance\n5. = Severe disability; bedridden, incontinent and requiring constant nursing care and attention\n6. = Dead","timeFrame":"At baseline, on Days 21 and 90, and at the time of a new stroke event"},{"measure":"Montreal Cognitive Assessment (MoCA)","description":"The Montreal Cognitive Assessment (MoCA) is a survey with a summed score. MoCA score ranges between a lowest score of 0 to a highest score of 30. A score of:\n\n* ≥26 points: indicates normal cognitive function\n* 18-25 points: Mild cognitive impairment\n* 10-17 points: Moderate cognitive impairment\n* fewer than 10 points: Severe cognitive impairment","timeFrame":"At baseline, on Days 21 and 90, and at the time of a new stroke event"},{"measure":"Digit Symbol Substitution Test (DSST)","description":"The Descriptive Summary of the Digit Symbol Substitution Test (DSST) is a scale item, with a lowest score of 0 and highest total score of 135. Higher score indicates better cognitive functioning.","timeFrame":"At baseline, on Days 21 and 90, and at the time of a new stroke event"},{"measure":"Number of Participants With Adverse Events (AEs)","description":"AE: include all non-serious adverse events with onset on or after first dose date and within 2 days after the last dose of study treatment.","timeFrame":"From first dose to 2 days after last dose of study therapy (up to approximately 107 days)"},{"measure":"Number of Participants With Clinically Significant Vital Sign Abnormalities","description":"Number of participants with clinically significant vital sign abnormalities. Vital signs included heart rate and diastolic and systolic blood pressure.","timeFrame":"From first dose to up to 90 days after first dose"},{"measure":"Number of Participants With Clinically Significant Physical Examination Abnormalities","description":"Number of participants with clinically significant physical examination abnormalities.","timeFrame":"From first dose to up to 90 days after first dose"},{"measure":"Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities","description":"Number of participants with clinically significant ECG abnormalities.","timeFrame":"From first dose to up to 90 days after first dose"},{"measure":"Number of Participants With Clinically Significant Laboratory Abnormalities - Liver","description":"The number of treated participants who experienced a laboratory abnormality of the liver during the course of the study.\n\nAspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN) Results reported in International System of Units (SI)","timeFrame":"From first dose to up to approximately 38 months"},{"measure":"Percent Change From Baseline in aPTT Activity","description":"Percent change from baseline in activated partial thromboplastin time (aPTT) activity via exposure response.","timeFrame":"Baseline and day 90"},{"measure":"Percent Change From Baseline in Factor XI Clotting Activity","description":"Percent change from baseline in factor XI clotting activity via exposure response.","timeFrame":"Baseline and day 90"},{"measure":"Pharmacokinetic Parameter - Estimated Clearance (CL)","description":"Pharmacokinetic Parameter - Estimated Clearance (CL). CL is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.","timeFrame":"From first dose to up to 90 days after first dose"},{"measure":"Pharmacokinetic Parameter - Volume of the Central Compartment (VC)","description":"Pharmacokinetic Parameter - Volume of the Central Compartment (VC). VC is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.","timeFrame":"From first dose to up to 90 days after first dose"},{"measure":"Volume of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI","description":"Total volume of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.","timeFrame":"At day 90"},{"measure":"Number of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI","description":"Number of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.","timeFrame":"At day 90"}],"otherOutcomes":[{"measure":"Percent of Participants With Ischemic Stroke Events","description":"Secondary analysis of symptomatic ischemic stroke events. Clinical events are included up to day 90. Wald 95% CI within group. Undetermined stroke is included.","timeFrame":"From randomization to up to 90 days after randomization"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and Female ≥40 years of age\n* Acute Ischemic Stroke or Transient Ischemic Attack\n* Intracranial or Extracranial Atherosclerotic Plaque proximal to the affected brain area\n\nExclusion Criteria:\n\n* Predicted inability to swallow study medication\n* Any condition that, in the opinion of the Investigator, contraindicates anticoagulant therapy or would have an unacceptable risk of bleeding\n* Use of thrombolytic therapy or mechanical thrombectomy for treatment of index stroke\n\nOther protocol defined inclusion/exclusion criteria could apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Bristol-Myers Squibb","affiliation":"Bristol-Myers Squibb","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Local Institution - 0029","city":"Birmingham","state":"Alabama","zip":"35233","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Local Institution - 0007","city":"Glendale","state":"California","zip":"91206","country":"United States","geoPoint":{"lat":34.14251,"lon":-118.25508}},{"facility":"Local Institution - 0006","city":"Long Beach","state":"California","zip":"90806","country":"United States","geoPoint":{"lat":33.76696,"lon":-118.18923}},{"facility":"Kaiser Permanente Los Angeles Medical Center","city":"Los Angeles","state":"California","zip":"90027","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Local Institution - 0231","city":"Los Angeles","state":"California","zip":"90095","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Local Institution - 0376","city":"Sacramento","state":"California","zip":"95817","country":"United States","geoPoint":{"lat":38.58157,"lon":-121.4944}},{"facility":"Local Institution - 0004","city":"Stanford","state":"California","zip":"94305","country":"United States","geoPoint":{"lat":37.42411,"lon":-122.16608}},{"facility":"Local Institution - 0042","city":"Torrance","state":"California","zip":"90502","country":"United States","geoPoint":{"lat":33.83585,"lon":-118.34063}},{"facility":"Local Institution - 0340","city":"Newark","state":"Delaware","zip":"19713","country":"United States","geoPoint":{"lat":39.68372,"lon":-75.74966}},{"facility":"Local Institution - 0075","city":"Gainesville","state":"Florida","zip":"32610","country":"United States","geoPoint":{"lat":29.65163,"lon":-82.32483}},{"facility":"Local Institution - 0013","city":"Sarasota","state":"Florida","zip":"34239","country":"United States","geoPoint":{"lat":27.33643,"lon":-82.53065}},{"facility":"Local Institution - 0024","city":"Tampa","state":"Florida","zip":"33606","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Local Institution - 0015","city":"Augusta","state":"Georgia","zip":"30912","country":"United States","geoPoint":{"lat":33.47097,"lon":-81.97484}},{"facility":"Local Institution - 0428","city":"Honolulu","state":"Hawaii","zip":"96813","country":"United States","geoPoint":{"lat":21.30694,"lon":-157.85833}},{"facility":"Local Institution - 0293","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"University of Illinois Hospital & Health Sciences System","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Local Institution - 0430","city":"Elk Grove Village","state":"Illinois","zip":"60007","country":"United States","geoPoint":{"lat":42.00392,"lon":-87.97035}},{"facility":"Local Institution - 0382","city":"Rockford","state":"Illinois","zip":"61114","country":"United States","geoPoint":{"lat":42.27113,"lon":-89.094}},{"facility":"Local Institution - 0346","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Local Institution - 0047","city":"New Orleans","state":"Louisiana","zip":"70121","country":"United States","geoPoint":{"lat":29.95465,"lon":-90.07507}},{"facility":"Local Institution - 0420","city":"Baltimore","state":"Maryland","zip":"21215","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Local Institution","city":"Boston","state":"Massachusetts","zip":"02118","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Local Institution - 0236","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Local Institution","city":"Detroit","state":"Michigan","zip":"48201","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Local Institution - 0434","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Local Institution","city":"Detroit","state":"Michigan","zip":"48235","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Local Institution - 0375","city":"Farmington Hills","state":"Michigan","zip":"48334","country":"United States","geoPoint":{"lat":42.48531,"lon":-83.37716}},{"facility":"Local Institution","city":"Minneapolis","state":"Minnesota","zip":"55415","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"Local Institution","city":"Kansas City","state":"Missouri","zip":"64111","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Local Institution","city":"Saint Louis","state":"Missouri","zip":"63104","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Local Institution - 0294","city":"Saint Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Local Institution - 0352","city":"Saint Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Advanced Neurology Specialists PLLC","city":"Great Falls","state":"Montana","zip":"59405","country":"United States","geoPoint":{"lat":47.50024,"lon":-111.30081}},{"facility":"Local Institution - 0276","city":"Camden","state":"New Jersey","zip":"08103","country":"United States","geoPoint":{"lat":39.92595,"lon":-75.11962}},{"facility":"Local Institution - 0039","city":"New Brunswick","state":"New Jersey","zip":"08901","country":"United States","geoPoint":{"lat":40.48622,"lon":-74.45182}},{"facility":"Local Institution - 0354","city":"Brooklyn","state":"New York","zip":"11203","country":"United States","geoPoint":{"lat":40.6501,"lon":-73.94958}},{"facility":"Local Institution","city":"Buffalo","state":"New York","zip":"14202","country":"United States","geoPoint":{"lat":42.88645,"lon":-78.87837}},{"facility":"Local Institution","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Local Institution - 0125","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Duke University Medical Center","city":"Butner","state":"North Carolina","zip":"27509-1626","country":"United States","geoPoint":{"lat":36.13209,"lon":-78.75667}},{"facility":"Local Institution - 0043","city":"Chapel Hill","state":"North Carolina","zip":"27599","country":"United States","geoPoint":{"lat":35.9132,"lon":-79.05584}},{"facility":"Local Institution - 0016","city":"Greensboro","state":"North Carolina","zip":"27405","country":"United States","geoPoint":{"lat":36.07264,"lon":-79.79198}},{"facility":"Local Institution","city":"Winston-Salem","state":"North Carolina","zip":"27157","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"Local Institution - 0003","city":"Cleveland","state":"Ohio","zip":"44106","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Local Institution - 0050","city":"Cleveland","state":"Ohio","zip":"44195","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Local Institution - 0419","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Local Institution - 0218","city":"Oklahoma City","state":"Oklahoma","zip":"73112","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Local Institution - 0022","city":"Portland","state":"Oregon","zip":"97239-3011","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Local Institution - 0302","city":"Abington","state":"Pennsylvania","zip":"19001","country":"United States","geoPoint":{"lat":40.12067,"lon":-75.11795}},{"facility":"Local Institution","city":"Allentown","state":"Pennsylvania","zip":"18103-6381","country":"United States","geoPoint":{"lat":40.60843,"lon":-75.49018}},{"facility":"Local Institution","city":"Camp Hill","state":"Pennsylvania","zip":"17011","country":"United States","geoPoint":{"lat":40.23981,"lon":-76.91997}},{"facility":"Local Institution - 0018","city":"Erie","state":"Pennsylvania","zip":"16550-0001","country":"United States","geoPoint":{"lat":42.12922,"lon":-80.08506}},{"facility":"Local Institution - 0020","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}},{"facility":"Temple University Hospital","city":"Philadelphia","state":"Pennsylvania","zip":"19140","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}},{"facility":"Local Institution - 0019","city":"York","state":"Pennsylvania","zip":"17403","country":"United States","geoPoint":{"lat":39.9626,"lon":-76.72774}},{"facility":"Local Institution - 0041","city":"Columbia","state":"South Carolina","zip":"29203","country":"United States","geoPoint":{"lat":34.00071,"lon":-81.03481}},{"facility":"Local Institution - 0009","city":"Nashville","state":"Tennessee","zip":"37232-6307","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Local Institution - 0008","city":"Austin","state":"Texas","zip":"78712","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Neurology Consultants of Dallas, PA","city":"Dallas","state":"Texas","zip":"75321","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Local Institution","city":"Dallas","state":"Texas","zip":"75390-88520","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"University Medical center of El Paso","city":"El Paso","state":"Texas","zip":"79905","country":"United States","geoPoint":{"lat":31.75872,"lon":-106.48693}},{"facility":"Local Institution - 0040","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Local Institution - 0093","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Local Institution - 0187","city":"Temple","state":"Texas","zip":"76508","country":"United States","geoPoint":{"lat":31.09823,"lon":-97.34278}},{"facility":"Local Institution","city":"Richmond","state":"Virginia","zip":"23298","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Local Institution","city":"Milwaukee","state":"Wisconsin","zip":"53226","country":"United States","geoPoint":{"lat":43.0389,"lon":-87.90647}},{"facility":"Local Institution - 0100","city":"Adrogué","state":"Buenos Aires","zip":"B1846DSK","country":"Argentina","geoPoint":{"lat":-34.80041,"lon":-58.38384}},{"facility":"Local Institution - 0063","city":"Caba","state":"Buenos Aires","zip":"C1199ABB","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Local Institution - 0076","city":"Caba","state":"Buenos Aires","zip":"C1428AQK","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Local Institution - 0067","city":"Ciudad Autonoma de Buenos Aires","state":"Buenos Aires","zip":"C1180AAX","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Local Institution - 0237","city":"Lomas de Zamora","state":"Buenos Aires","zip":"1832","country":"Argentina","geoPoint":{"lat":-34.76088,"lon":-58.40632}},{"facility":"Local Institution - 0435","city":"Recoleta","state":"Buenos Aires","zip":"C1115AAB","country":"Argentina","geoPoint":{"lat":-34.58333,"lon":-58.4}},{"facility":"Local Institution","city":"Buenos Aires","zip":"1437","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Local Institution - 0068","city":"Buenos Aires","zip":"C1425DND","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Local Institution","city":"Buenos Aires","zip":"C1425","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Local Institution","city":"Santa Fe","zip":"3000","country":"Argentina","geoPoint":{"lat":-31.63333,"lon":-60.7}},{"facility":"Local Institution - 0329","city":"Randwick","state":"New South Wales","zip":"2031","country":"Australia","geoPoint":{"lat":-33.91439,"lon":151.24895}},{"facility":"Local Institution - 0360","city":"Sydney","state":"New South Wales","zip":"2170","country":"Australia","geoPoint":{"lat":-33.86785,"lon":151.20732}},{"facility":"Local Institution - 0287","city":"Southport","state":"Queensland","zip":"4215","country":"Australia","geoPoint":{"lat":-27.96724,"lon":153.39796}},{"facility":"Local Institution - 0399","city":"Adelaide","state":"South Australia","zip":"5000","country":"Australia","geoPoint":{"lat":-34.92866,"lon":138.59863}},{"facility":"Local Institution - 0397","city":"Launceston","state":"Tasmania","zip":"7250","country":"Australia","geoPoint":{"lat":-41.43876,"lon":147.13467}},{"facility":"Local Institution - 0358","city":"Clayton","state":"Victoria","zip":"3168","country":"Australia","geoPoint":{"lat":-37.91667,"lon":145.11667}},{"facility":"Local Institution - 0281","city":"Heidelberg","state":"Victoria","zip":"3084","country":"Australia","geoPoint":{"lat":-37.75,"lon":145.06667}},{"facility":"Local Institution - 0315","city":"Murdoch","state":"Western Australia","zip":"6150","country":"Australia","geoPoint":{"lat":-32.06987,"lon":115.83757}},{"facility":"Local Institution - 0184","city":"Klagenfurt Am Woerthersee","zip":"9020","country":"Austria"},{"facility":"Local Institution","city":"St. Pölten","zip":"3100","country":"Austria","geoPoint":{"lat":48.2,"lon":15.63333}},{"facility":"Local Institution - 0106","city":"Vocklabruck","zip":"4840","country":"Austria","geoPoint":{"lat":48.00291,"lon":13.65647}},{"facility":"Local Institution - 0273","city":"Wien","zip":"1160","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"Local Institution - 0122","city":"Edegem","state":"Antwerpen","zip":"2650","country":"Belgium","geoPoint":{"lat":51.15662,"lon":4.44504}},{"facility":"Local Institution - 0196","city":"Brussel","state":"Brussels","zip":"1090","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Local Institution - 0192","city":"Yvoir","state":"Namur","zip":"5530","country":"Belgium","geoPoint":{"lat":50.3279,"lon":4.88059}},{"facility":"Local Institution","city":"Brasschaat","zip":"2930","country":"Belgium","geoPoint":{"lat":51.2912,"lon":4.49182}},{"facility":"Local Institution - 0284","city":"Bruges","zip":"8000","country":"Belgium","geoPoint":{"lat":51.20892,"lon":3.22424}},{"facility":"Local Institution - 0427","city":"Brussels","zip":"1020","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Local Institution - 0190","city":"Brussels","zip":"1200","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Local Institution - 0305","city":"Bruxelles","zip":"1070","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Local Institution - 0199","city":"Gent","zip":"9000","country":"Belgium","geoPoint":{"lat":51.05,"lon":3.71667}},{"facility":"Local Institution - 0103","city":"Kortrijk","zip":"8500","country":"Belgium","geoPoint":{"lat":50.82803,"lon":3.26487}},{"facility":"Local Institution - 0098","city":"Leuven","zip":"3000","country":"Belgium","geoPoint":{"lat":50.87959,"lon":4.70093}},{"facility":"Local Institution - 0178","city":"Liege","zip":"4000","country":"Belgium","geoPoint":{"lat":50.63373,"lon":5.56749}},{"facility":"Local Institution - 0072","city":"Fortaleza","state":"Ceara","zip":"60175-295","country":"Brazil","geoPoint":{"lat":-3.71722,"lon":-38.54306}},{"facility":"Local Institution - 0275","city":"Uberaba","state":"Minas Gerais","zip":"38025-260","country":"Brazil","geoPoint":{"lat":-19.74833,"lon":-47.93194}},{"facility":"Local Institution - 0314","city":"Curitiba","state":"Parana","zip":"80060-900","country":"Brazil","geoPoint":{"lat":-25.42778,"lon":-49.27306}},{"facility":"Local Institution - 0200","city":"Porto Alegre","state":"Rio Grande Do Sul","zip":"90035-903","country":"Brazil","geoPoint":{"lat":-30.03306,"lon":-51.23}},{"facility":"Local Institution - 0219","city":"Joinville","state":"Santa Catarina","zip":"89202 165","country":"Brazil","geoPoint":{"lat":-26.30444,"lon":-48.84556}},{"facility":"Local Institution - 0245","city":"Botucatu","state":"SAO Paulo","zip":"18618-686","country":"Brazil","geoPoint":{"lat":-22.88583,"lon":-48.445}},{"facility":"Local Institution - 0065","city":"Campinas","state":"SAO Paulo","zip":"13083-970","country":"Brazil","geoPoint":{"lat":-22.90556,"lon":-47.06083}},{"facility":"Local Institution","city":"Ribeirao Preto","state":"SAO Paulo","zip":"14051-140","country":"Brazil","geoPoint":{"lat":-21.1775,"lon":-47.81028}},{"facility":"Local Institution - 0113","city":"Santo Andre","state":"SAO Paulo","zip":"09030-010","country":"Brazil","geoPoint":{"lat":-23.66389,"lon":-46.53833}},{"facility":"Local Institution - 0234","city":"São Paulo","state":"SAO Paulo","zip":"01221-020","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Local Institution - 0248","city":"São Paulo","state":"SAO Paulo","zip":"04024-002","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Local Institution - 0057","city":"Calgary","state":"Alberta","zip":"T2N 2T9","country":"Canada","geoPoint":{"lat":51.05011,"lon":-114.08529}},{"facility":"Local Institution - 0061","city":"Edmonton","state":"Alberta","zip":"T6G 2G3","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Local Institution - 0059","city":"Lethbridge","state":"Alberta","zip":"T1J 0N9","country":"Canada","geoPoint":{"lat":49.69999,"lon":-112.81856}},{"facility":"Local Institution - 0369","city":"New Westminster","state":"British Columbia","zip":"V3L 0E3","country":"Canada","geoPoint":{"lat":49.20678,"lon":-122.91092}},{"facility":"Local Institution - 0121","city":"Vancouver","state":"British Columbia","zip":"V5Z 1M9","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"Local Institution - 0054","city":"Hamilton","state":"Ontario","zip":"L8L 2X2","country":"Canada","geoPoint":{"lat":43.25011,"lon":-79.84963}},{"facility":"Local Institution","city":"Kingston","state":"Ontario","zip":"K7L 2V7","country":"Canada","geoPoint":{"lat":44.22976,"lon":-76.48101}},{"facility":"Local Institution - 0227","city":"London","state":"Ontario","zip":"N6A 5A5","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"Local Institution - 0124","city":"Toronto","state":"Ontario","zip":"M4N 3M5","country":"Canada","geoPoint":{"lat":43.70011,"lon":-79.4163}},{"facility":"Local Institution","city":"Toronto","state":"Ontario","zip":"M5B 1W8","country":"Canada","geoPoint":{"lat":43.70011,"lon":-79.4163}},{"facility":"Local Institution - 0326","city":"Chicoutimi","state":"Quebec","zip":"G7H 5H6","country":"Canada","geoPoint":{"lat":48.41963,"lon":-71.06369}},{"facility":"Local Institution - 0155","city":"Greenfield Park","state":"Quebec","zip":"J4V 2H1","country":"Canada","geoPoint":{"lat":45.48649,"lon":-73.46223}},{"facility":"Local Institution - 0066","city":"Montreal","state":"Quebec","zip":"H4A3J1","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Local Institution - 0064","city":"Quebec","zip":"G1J 1Z4","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"Local Institution - 0172","city":"Viña del Mar","state":"Valparaiso","zip":"2520612","country":"Chile","geoPoint":{"lat":-33.02457,"lon":-71.55183}},{"facility":"Local Institution","city":"Los Angeles","zip":"441055","country":"Chile","geoPoint":{"lat":-37.46973,"lon":-72.35366}},{"facility":"Local Institution - 0131","city":"Valdivia","zip":"5090145","country":"Chile","geoPoint":{"lat":-39.81422,"lon":-73.24589}},{"facility":"Local Institution - 0167","city":"Viña del Mar","zip":"0","country":"Chile","geoPoint":{"lat":-33.02457,"lon":-71.55183}},{"facility":"Local Institution","city":"Beijing","state":"Beijing","zip":"100070","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Local Institution","city":"Guangzhou","state":"Guangdong","zip":"510080","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Local Institution","city":"Haikou","state":"Hainan","zip":"570311","country":"China","geoPoint":{"lat":20.04583,"lon":110.34167}},{"facility":"Local Institution","city":"Daqing","state":"Heilongjiang","zip":"163001","country":"China","geoPoint":{"lat":46.58333,"lon":125.0}},{"facility":"Local Institution","city":"Zhengzhou","state":"Henan","zip":"450052","country":"China","geoPoint":{"lat":34.75778,"lon":113.64861}},{"facility":"Local Institution","city":"Nantong","state":"Jiangsu","zip":"226001","country":"China","geoPoint":{"lat":32.03028,"lon":120.87472}},{"facility":"Local Institution","city":"Yangzhou","state":"Jiangsu","zip":"225001","country":"China","geoPoint":{"lat":32.39722,"lon":119.43583}},{"facility":"Local Institution","city":"Changchun","state":"Jilin","zip":"130021","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"Local Institution","city":"Shenyang","state":"Liaoning","zip":"110016","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}},{"facility":"Local Institution","city":"Qingdao","state":"Shandong","zip":"266000","country":"China","geoPoint":{"lat":36.06488,"lon":120.38042}},{"facility":"Local Institution","city":"YanTai","state":"Shandong","zip":"264000","country":"China","geoPoint":{"lat":37.47649,"lon":121.44081}},{"facility":"Local Institution","city":"Wenzhou","state":"Zhejiang","zip":"325000","country":"China","geoPoint":{"lat":27.99942,"lon":120.66682}},{"facility":"Local Institution - 0401","city":"Olomouc","state":"Olomoucký Kraj","zip":"779 00","country":"Czechia","geoPoint":{"lat":49.59552,"lon":17.25175}},{"facility":"Local Institution - 0348","city":"Jihlava","state":"Vysocina","zip":"586 01","country":"Czechia","geoPoint":{"lat":49.3961,"lon":15.59124}},{"facility":"Local Institution","city":"Brno","zip":"656 91","country":"Czechia","geoPoint":{"lat":49.19522,"lon":16.60796}},{"facility":"Local Institution","city":"Ceske Budejovice","zip":"370 87","country":"Czechia","geoPoint":{"lat":48.97447,"lon":14.47434}},{"facility":"Local Institution - 0023","city":"Ostrava","zip":"703 00","country":"Czechia","geoPoint":{"lat":49.83465,"lon":18.28204}},{"facility":"Local Institution - 0339","city":"Praha 2","zip":"128 08","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Local Institution - 0117","city":"Herlev","state":"Capital","zip":"2730","country":"Denmark","geoPoint":{"lat":55.72366,"lon":12.43998}},{"facility":"Local Institution - 0217","city":"Aalborg","zip":"9000","country":"Denmark","geoPoint":{"lat":57.048,"lon":9.9187}},{"facility":"Local Institution - 0127","city":"Aarhus N","zip":"8200","country":"Denmark","geoPoint":{"lat":56.15674,"lon":10.21076}},{"facility":"Local Institution - 0142","city":"Copenhagen","zip":"2400","country":"Denmark","geoPoint":{"lat":55.67594,"lon":12.56553}},{"facility":"Local Institution - 0110","city":"Glostrup","zip":"2600","country":"Denmark","geoPoint":{"lat":55.6666,"lon":12.40377}},{"facility":"Local Institution - 0111","city":"Helsinki","zip":"290","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"Local Institution - 0341","city":"Lappeenranta","zip":"53130","country":"Finland","geoPoint":{"lat":61.05871,"lon":28.18871}},{"facility":"Local Institution - 0143","city":"Turku","zip":"FI-20520","country":"Finland","geoPoint":{"lat":60.45148,"lon":22.26869}},{"facility":"Local Institution - 0442","city":"Montpellier","state":"Hérault","zip":"34295","country":"France","geoPoint":{"lat":43.61092,"lon":3.87723}},{"facility":"Local Institution - 0048","city":"Lille","state":"Nord","zip":"59037","country":"France","geoPoint":{"lat":50.63297,"lon":3.05858}},{"facility":"Local Institution - 0051","city":"Bordeaux","zip":"33000","country":"France","geoPoint":{"lat":44.84044,"lon":-0.5805}},{"facility":"Local Institution","city":"Bourg-en-Bresse","zip":"01012","country":"France","geoPoint":{"lat":46.20574,"lon":5.2258}},{"facility":"Local Institution - 0165","city":"Brest","zip":"29200","country":"France","geoPoint":{"lat":48.3903,"lon":-4.48628}},{"facility":"Local Institution - 0174","city":"Caen","zip":"14033","country":"France","geoPoint":{"lat":49.18585,"lon":-0.35912}},{"facility":"Local Institution","city":"Créteil","zip":"94010","country":"France","geoPoint":{"lat":48.78333,"lon":2.46667}},{"facility":"Local Institution","city":"Limoges Cedex","zip":"87042","country":"France","geoPoint":{"lat":45.83153,"lon":1.25781}},{"facility":"Local Institution - 0168","city":"Marseille","zip":"13385","country":"France","geoPoint":{"lat":43.29551,"lon":5.38958}},{"facility":"Local Institution - 0297","city":"Nancy","zip":"54035","country":"France","geoPoint":{"lat":48.68439,"lon":6.18496}},{"facility":"Local Institution - 0205","city":"Nimes","zip":"30029","country":"France","geoPoint":{"lat":43.83333,"lon":4.35}},{"facility":"Local Institution - 0049","city":"Paris","zip":"75010","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Local Institution","city":"Paris","zip":"75013","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Local Institution - 0126","city":"Paris","zip":"75019","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Local Institution - 0028","city":"Paris","zip":"75877","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Local Institution - 0107","city":"Rouen Cedex","zip":"76031","country":"France","geoPoint":{"lat":49.44313,"lon":1.09932}},{"facility":"Local Institution - 0355","city":"Toulouse Cedex 9","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Local Institution - 0391","city":"Sindelfingen","state":"Baden-Württemberg","zip":"71065","country":"Germany","geoPoint":{"lat":48.7,"lon":9.01667}},{"facility":"Local Institution - 0045","city":"Tübingen","state":"Baden-Württemberg","zip":"72076","country":"Germany","geoPoint":{"lat":48.52266,"lon":9.05222}},{"facility":"Local Institution - 0285","city":"Frankfurt am Main","state":"Hessen","zip":"65929","country":"Germany","geoPoint":{"lat":50.11552,"lon":8.68417}},{"facility":"Local Institution - 0090","city":"Leipzig","state":"Sachsen","zip":"04103","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"facility":"Local Institution - 0258","city":"Lübeck","state":"Schleswig-Holstein","zip":"23538","country":"Germany","geoPoint":{"lat":53.86893,"lon":10.68729}},{"facility":"Local Institution - 0011","city":"Altenburg","zip":"04600","country":"Germany","geoPoint":{"lat":50.98763,"lon":12.43684}},{"facility":"Local Institution - 0032","city":"Berlin","zip":"12203","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Local Institution","city":"Berlin","zip":"12351","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Local Institution","city":"Bielefeld","zip":"33617","country":"Germany","geoPoint":{"lat":52.03333,"lon":8.53333}},{"facility":"Local Institution - 0250","city":"Bonn","zip":"53127","country":"Germany","geoPoint":{"lat":50.73438,"lon":7.09549}},{"facility":"Local Institution - 0380","city":"Bremen","zip":"28755","country":"Germany","geoPoint":{"lat":53.07516,"lon":8.80777}},{"facility":"Local Institution - 0144","city":"Dresden","zip":"01307","country":"Germany","geoPoint":{"lat":51.05089,"lon":13.73832}},{"facility":"Local Institution - 0097","city":"Erlangen","zip":"91054","country":"Germany","geoPoint":{"lat":49.59099,"lon":11.00783}},{"facility":"Local Institution - 0053","city":"Essen","zip":"45131","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"Local Institution - 0291","city":"Frankfurt am Main","zip":"60528","country":"Germany","geoPoint":{"lat":50.11552,"lon":8.68417}},{"facility":"Local Institution - 0254","city":"Gießen","zip":"35392","country":"Germany","geoPoint":{"lat":50.58727,"lon":8.67554}},{"facility":"Local Institution - 0056","city":"Hamburg","zip":"20246","country":"Germany","geoPoint":{"lat":53.57532,"lon":10.01534}},{"facility":"Local Institution - 0044","city":"Hamburg","zip":"22043","country":"Germany","geoPoint":{"lat":53.57532,"lon":10.01534}},{"facility":"Local Institution - 0034","city":"Hamburg","zip":"22763","country":"Germany","geoPoint":{"lat":53.57532,"lon":10.01534}},{"facility":"Local Institution","city":"Hannover","zip":"D30625","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"Local Institution - 0055","city":"Heidelberg","zip":"69120","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Local Institution","city":"Magdeburg","zip":"39120","country":"Germany","geoPoint":{"lat":52.12773,"lon":11.62916}},{"facility":"Local Institution - 0036","city":"Minden","zip":"32429","country":"Germany","geoPoint":{"lat":52.28953,"lon":8.91455}},{"facility":"Local Institution - 0256","city":"Münster","zip":"48149","country":"Germany","geoPoint":{"lat":51.96236,"lon":7.62571}},{"facility":"Local Institution - 0378","city":"Osnabruck","zip":"49076","country":"Germany","geoPoint":{"lat":52.27264,"lon":8.0498}},{"facility":"Local Institution - 0367","city":"Regensburg","zip":"93053","country":"Germany","geoPoint":{"lat":49.01513,"lon":12.10161}},{"facility":"Local Institution - 0387","city":"Sande","zip":"26452","country":"Germany","geoPoint":{"lat":53.50489,"lon":8.01418}},{"facility":"Local Institution","city":"Siegen","zip":"57076","country":"Germany","geoPoint":{"lat":50.87481,"lon":8.02431}},{"facility":"Local Institution - 0241","city":"Ulm","zip":"89081","country":"Germany","geoPoint":{"lat":48.39841,"lon":9.99155}},{"facility":"Local Institution - 0438","city":"Athina","state":"Attiki","zip":"115 21","country":"Greece"},{"facility":"Local Institution - 0357","city":"Larissa","state":"Larisa","zip":"41110","country":"Greece","geoPoint":{"lat":39.63689,"lon":22.41761}},{"facility":"Local Institution - 0370","city":"Athens","zip":"106 76","country":"Greece","geoPoint":{"lat":37.97945,"lon":23.71622}},{"facility":"Local Institution - 0436","city":"Athens","zip":"11525","country":"Greece","geoPoint":{"lat":37.97945,"lon":23.71622}},{"facility":"Local Institution - 0440","city":"Athens","zip":"11526","country":"Greece","geoPoint":{"lat":37.97945,"lon":23.71622}},{"facility":"Local Institution - 0373","city":"Athens","zip":"11527","country":"Greece","geoPoint":{"lat":37.97945,"lon":23.71622}},{"facility":"Local Institution","city":"Athens","zip":"11527","country":"Greece","geoPoint":{"lat":37.97945,"lon":23.71622}},{"facility":"Local Institution - 0209","city":"Athens","zip":"11528","country":"Greece","geoPoint":{"lat":37.97945,"lon":23.71622}},{"facility":"Local Institution - 0283","city":"Athens","zip":"11528","country":"Greece","geoPoint":{"lat":37.97945,"lon":23.71622}},{"facility":"Local Institution - 0351","city":"Athens","zip":"12461","country":"Greece","geoPoint":{"lat":37.97945,"lon":23.71622}},{"facility":"Local Institution - 0407","city":"Crete","zip":"71110","country":"Greece"},{"facility":"Local Institution","city":"Ioannina","zip":"45445","country":"Greece","geoPoint":{"lat":39.66486,"lon":20.85189}},{"facility":"Local Institution - 0161","city":"Larissa","zip":"41110","country":"Greece","geoPoint":{"lat":39.63689,"lon":22.41761}},{"facility":"Local Institution - 0441","city":"Larissa","zip":"41221","country":"Greece","geoPoint":{"lat":39.63689,"lon":22.41761}},{"facility":"Local Institution - 0333","city":"Loanniana","zip":"45500","country":"Greece"},{"facility":"Local Institution - 0365","city":"Loanniana","zip":"45500","country":"Greece"},{"facility":"Local Institution - 0439","city":"Neo Faliro","zip":"18547","country":"Greece","geoPoint":{"lat":37.9464,"lon":23.66736}},{"facility":"Local Institution - 0371","city":"Patras","zip":"26500","country":"Greece","geoPoint":{"lat":38.24444,"lon":21.73444}},{"facility":"Local Institution - 0208","city":"Pireaus","zip":"18536","country":"Greece"},{"facility":"Local Institution - 0405","city":"Thessaloniki","zip":"54621","country":"Greece","geoPoint":{"lat":40.64361,"lon":22.93086}},{"facility":"Local Institution - 0269","city":"Thessaloniki","zip":"54636","country":"Greece","geoPoint":{"lat":40.64361,"lon":22.93086}},{"facility":"Local Institution - 0389","city":"Thessaloniki","zip":"54636","country":"Greece","geoPoint":{"lat":40.64361,"lon":22.93086}},{"facility":"Local Institution - 0444","city":"Thessaloniki","zip":"54642","country":"Greece","geoPoint":{"lat":40.64361,"lon":22.93086}},{"facility":"Local Institution - 0210","city":"Thessaloniki","zip":"56403","country":"Greece","geoPoint":{"lat":40.64361,"lon":22.93086}},{"facility":"Local Institution - 0445","city":"Thessaloniki","zip":"57010","country":"Greece","geoPoint":{"lat":40.64361,"lon":22.93086}},{"facility":"Local Institution","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Local Institution - 0070","city":"Miskolc","state":"BZ","zip":"3526","country":"Hungary","geoPoint":{"lat":48.1,"lon":20.78333}},{"facility":"Local Institution - 0134","city":"Budapest","zip":"1083","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Local Institution - 0077","city":"Budapest","zip":"1106","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Local Institution - 0119","city":"Budapest","zip":"1134","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Local Institution - 0136","city":"Budapest","zip":"1145","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Local Institution - 0154","city":"Debrecen","zip":"4032","country":"Hungary","geoPoint":{"lat":47.53333,"lon":21.63333}},{"facility":"Local Institution - 0079","city":"Gyor","zip":"9024","country":"Hungary","geoPoint":{"lat":47.68333,"lon":17.63512}},{"facility":"Local Institution - 0175","city":"Kistarcsa","zip":"02143","country":"Hungary","geoPoint":{"lat":47.54757,"lon":19.26247}},{"facility":"Local Institution - 0437","city":"Kisvárda","zip":"4600","country":"Hungary","geoPoint":{"lat":48.21667,"lon":22.08333}},{"facility":"Local Institution - 0220","city":"Nyíregyháza","zip":"4400","country":"Hungary","geoPoint":{"lat":47.95539,"lon":21.71671}},{"facility":"Local Institution - 0138","city":"Pecs","zip":"7624","country":"Hungary","geoPoint":{"lat":46.08333,"lon":18.23333}},{"facility":"Local Institution - 0133","city":"Szeged","zip":"6725","country":"Hungary","geoPoint":{"lat":46.253,"lon":20.14824}},{"facility":"Local Institution - 0137","city":"Zalaegerszeg","zip":"8900","country":"Hungary","geoPoint":{"lat":46.84,"lon":16.84389}},{"facility":"Local Institution","city":"Beer-Sheva","zip":"85025","country":"Israel","geoPoint":{"lat":31.25181,"lon":34.7913}},{"facility":"Local Institution - 0139","city":"Haifa","zip":"3109601","country":"Israel","geoPoint":{"lat":32.81841,"lon":34.9885}},{"facility":"Local Institution - 0349","city":"Haifa","zip":"34362","country":"Israel","geoPoint":{"lat":32.81841,"lon":34.9885}},{"facility":"Local Institution - 0193","city":"Jerusalem","zip":"9103102","country":"Israel","geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Local Institution","city":"Jerusalem","zip":"91031","country":"Israel","geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Local Institution - 0078","city":"Jerusalem","zip":"91120","country":"Israel","geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Local Institution - 0308","city":"Nahariya","zip":"22100","country":"Israel","geoPoint":{"lat":33.00892,"lon":35.09814}},{"facility":"Local Institution - 0247","city":"Petah Tikva","zip":"49100","country":"Israel","geoPoint":{"lat":32.08707,"lon":34.88747}},{"facility":"Local Institution - 0204","city":"Ramat-Gan","zip":"52621","country":"Israel","geoPoint":{"lat":32.08227,"lon":34.81065}},{"facility":"Local Institution - 0086","city":"Tel Aviv","zip":"64239","country":"Israel","geoPoint":{"lat":32.08088,"lon":34.78057}},{"facility":"Local Institution - 0359","city":"Genova","state":"Liguria","zip":"16132","country":"Italy","geoPoint":{"lat":44.40478,"lon":8.94438}},{"facility":"Local Institution - 0084","city":"Pavia","state":"Lombardia","zip":"27100","country":"Italy","geoPoint":{"lat":45.19205,"lon":9.15917}},{"facility":"Local Institution - 0151","city":"Ancona","state":"Marche","zip":"60020","country":"Italy","geoPoint":{"lat":43.5942,"lon":13.50337}},{"facility":"Local Institution - 0149","city":"Negrar","state":"Veneto","zip":"37024","country":"Italy","geoPoint":{"lat":45.52918,"lon":10.93899}},{"facility":"Local Institution - 0156","city":"Bologna","zip":"40133","country":"Italy","geoPoint":{"lat":44.49381,"lon":11.33875}},{"facility":"Local Institution - 0290","city":"Cagliari","zip":"09134","country":"Italy","geoPoint":{"lat":39.23054,"lon":9.11917}},{"facility":"Local Institution - 0095","city":"Milano","zip":"20132","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"facility":"Local Institution - 0104","city":"Modena","zip":"1355-41126","country":"Italy","geoPoint":{"lat":44.64783,"lon":10.92539}},{"facility":"Local Institution - 0085","city":"Perugia","zip":"06012","country":"Italy","geoPoint":{"lat":43.1122,"lon":12.38878}},{"facility":"Local Institution - 0114","city":"Perugia","zip":"06129","country":"Italy","geoPoint":{"lat":43.1122,"lon":12.38878}},{"facility":"Local Institution - 0108","city":"Roma","zip":"00152","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Local Institution - 0129","city":"Roma","zip":"00161","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Local Institution - 0083","city":"Verona","zip":"37126","country":"Italy","geoPoint":{"lat":45.4299,"lon":10.98444}},{"facility":"Local Institution - 0123","city":"Vibo Valentia","zip":"89900","country":"Italy","geoPoint":{"lat":38.67618,"lon":16.10094}},{"facility":"Local Institution - 0335","city":"Kasugai","state":"Aichi","zip":"487-0016","country":"Japan","geoPoint":{"lat":35.24762,"lon":136.97229}},{"facility":"Local Institution - 0274","city":"Nagoya-shi","state":"Aichi","zip":"4600001","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Local Institution - 0331","city":"Toyoake Shi","state":"Aichi","zip":"4701192","country":"Japan","geoPoint":{"lat":35.038,"lon":136.99931}},{"facility":"Local Institution - 0325","city":"Toyohashi-shi","state":"Aichi","zip":"440-8510","country":"Japan","geoPoint":{"lat":34.76667,"lon":137.38333}},{"facility":"Local Institution - 0317","city":"Toyota-shi","state":"Aichi","zip":"471-8513","country":"Japan","geoPoint":{"lat":35.08333,"lon":137.15}},{"facility":"Local Institution - 0336","city":"Sakura-shi","state":"Chiba","zip":"285-8741","country":"Japan","geoPoint":{"lat":35.71667,"lon":140.23333}},{"facility":"Local Institution - 0320","city":"Chikushino-shi","state":"Fukuoka","zip":"818-8516","country":"Japan","geoPoint":{"lat":33.49631,"lon":130.5156}},{"facility":"Local Institution - 0259","city":"Kasuga-shi","state":"Fukuoka","zip":"816-0864","country":"Japan"},{"facility":"Local Institution - 0229","city":"Kitakyushu-shi","state":"Fukuoka","zip":"802-8555","country":"Japan","geoPoint":{"lat":33.85181,"lon":130.85034}},{"facility":"Local Institution - 0270","city":"Kitakyushu-shi","state":"Fukuoka","zip":"8058508","country":"Japan","geoPoint":{"lat":33.85181,"lon":130.85034}},{"facility":"Local Institution - 0311","city":"Kitakyushu","state":"Fukuoka","zip":"800-0296","country":"Japan","geoPoint":{"lat":33.85181,"lon":130.85034}},{"facility":"Local Institution - 0230","city":"Koga-shi","state":"Fukuoka","zip":"811-3113","country":"Japan","geoPoint":{"lat":33.73333,"lon":130.46667}},{"facility":"Local Institution - 0324","city":"Kurume City","state":"Fukuoka","zip":"830-8577","country":"Japan","geoPoint":{"lat":33.31667,"lon":130.51667}},{"facility":"Local Institution - 0257","city":"Aizuwakamatsu-shi","state":"Fukushima","zip":"9658585","country":"Japan"},{"facility":"Local Institution - 0309","city":"Takayama-shi","state":"Gifu","zip":"506-8550","country":"Japan","geoPoint":{"lat":36.13333,"lon":137.25}},{"facility":"Local Institution - 0211","city":"Isesaki-shi","state":"Gunma","zip":"372-0006","country":"Japan","geoPoint":{"lat":36.31667,"lon":139.2}},{"facility":"Local Institution - 0337","city":"Aki-gun","state":"Hiroshima","zip":"735-8585","country":"Japan","geoPoint":{"lat":33.5,"lon":133.9}},{"facility":"Local Institution - 0240","city":"Higashihiroshima-shi","state":"Hiroshima","zip":"739-0041","country":"Japan","geoPoint":{"lat":34.40861,"lon":132.73682}},{"facility":"Local Institution - 0328","city":"Hiroshima-shi","state":"Hiroshima","zip":"731-0293","country":"Japan","geoPoint":{"lat":34.4,"lon":132.45}},{"facility":"Local Institution - 0226","city":"Kobe-City","state":"Hyogo","zip":"650-0047","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"Local Institution - 0323","city":"Kanazawa","state":"Ishikawa","zip":"920-8650","country":"Japan","geoPoint":{"lat":36.6,"lon":136.61667}},{"facility":"Local Institution - 0446","city":"Komatsu","state":"Ishikawa","zip":"923-8560","country":"Japan","geoPoint":{"lat":36.40263,"lon":136.45088}},{"facility":"Local Institution - 0299","city":"Kagoshima-shi","state":"Kagoshima","zip":"890-8760","country":"Japan","geoPoint":{"lat":31.56667,"lon":130.55}},{"facility":"Local Institution - 0228","city":"Kawasaki-city","state":"Kanagawa","zip":"216-8511","country":"Japan","geoPoint":{"lat":35.52056,"lon":139.71722}},{"facility":"Local Institution - 0310","city":"Kawasaki","state":"Kanagawa","zip":"211-0063","country":"Japan","geoPoint":{"lat":35.52056,"lon":139.71722}},{"facility":"Local Institution - 0296","city":"Sendai-shi","state":"Miyagi","zip":"982-8523","country":"Japan","geoPoint":{"lat":38.26667,"lon":140.86667}},{"facility":"Local Institution - 0278","city":"Sendai","state":"Miyagi","zip":"9838520","country":"Japan","geoPoint":{"lat":38.26667,"lon":140.86667}},{"facility":"Local Institution - 0261","city":"Nagasaki-shi","state":"Nagasaki","zip":"8528501","country":"Japan","geoPoint":{"lat":32.75,"lon":129.88333}},{"facility":"Local Institution - 0272","city":"Izumisano-shi","state":"Osaka","zip":"5988577","country":"Japan","geoPoint":{"lat":34.41663,"lon":135.31667}},{"facility":"Local Institution","city":"Kishiwada","state":"Osaka","zip":"596-8522","country":"Japan","geoPoint":{"lat":34.46667,"lon":135.36667}},{"facility":"Local Institution - 0279","city":"Matsubara","state":"Osaka","zip":"580-0032","country":"Japan","geoPoint":{"lat":34.56667,"lon":135.55}},{"facility":"Local Institution - 0322","city":"Sakai-shi","state":"Osaka","zip":"590-0064","country":"Japan","geoPoint":{"lat":34.58333,"lon":135.46667}},{"facility":"Local Institution - 0244","city":"Suita-shi","state":"Osaka","zip":"565-0871","country":"Japan","geoPoint":{"lat":34.76143,"lon":135.51567}},{"facility":"Local Institution - 0251","city":"Suita","state":"Osaka","zip":"5648565","country":"Japan","geoPoint":{"lat":34.76143,"lon":135.51567}},{"facility":"Local Institution - 0263","city":"Hidaka","state":"Saitama","zip":"858+6","country":"Japan"},{"facility":"Local Institution - 0334","city":"Shimotsuke-shi","state":"Tochigi","zip":"3290498","country":"Japan","geoPoint":{"lat":36.41323,"lon":139.86622}},{"facility":"Local Institution - 0232","city":"Bunkyo-ku","state":"Tokyo","zip":"113-8603","country":"Japan","geoPoint":{"lat":35.37517,"lon":139.92991}},{"facility":"Local Institution - 0343","city":"Hachioji","state":"Tokyo","zip":"192-0032","country":"Japan","geoPoint":{"lat":35.65583,"lon":139.32389}},{"facility":"Local Institution - 0255","city":"Meguro-ku","state":"Tokyo","zip":"152-8902","country":"Japan","geoPoint":{"lat":42.12755,"lon":143.31736}},{"facility":"Local Institution - 0338","city":"Minato-ku","state":"Tokyo","zip":"1058471","country":"Japan","geoPoint":{"lat":34.2152,"lon":135.1501}},{"facility":"Local Institution - 0342","city":"Minato-ku","state":"Tokyo","zip":"108-0073","country":"Japan","geoPoint":{"lat":34.2152,"lon":135.1501}},{"facility":"Local Institution - 0295","city":"Mitaka-shi","state":"Tokyo","zip":"181-8611","country":"Japan","geoPoint":{"lat":35.68351,"lon":139.55963}},{"facility":"Local Institution - 0298","city":"Shinagawa-ku","state":"Tokyo","zip":"141-8625","country":"Japan","geoPoint":{"lat":33.63627,"lon":133.00572}},{"facility":"Local Institution - 0316","city":"Shinjuku-ku","state":"Tokyo","zip":"160-8582","country":"Japan","geoPoint":{"lat":35.2946,"lon":139.57059}},{"facility":"Local Institution - 0318","city":"Tachikawa-shi","state":"Tokyo","zip":"1900014","country":"Japan"},{"facility":"Local Institution - 0319","city":"Shimonoseki-Shi","state":"Yamaguchi","zip":"752-8510","country":"Japan","geoPoint":{"lat":33.95001,"lon":130.94999}},{"facility":"Local Institution - 0271","city":"Fukuoka","zip":"810-0001","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Local Institution - 0243","city":"Fukuoka","zip":"810-8563","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Local Institution - 0312","city":"Kyoto","zip":"6008558","country":"Japan","geoPoint":{"lat":35.02107,"lon":135.75385}},{"facility":"Local Institution - 0327","city":"Osaka","zip":"533-0024","country":"Japan","geoPoint":{"lat":34.69374,"lon":135.50218}},{"facility":"Local Institution - 0239","city":"Osaka","zip":"540-0006","country":"Japan","geoPoint":{"lat":34.69374,"lon":135.50218}},{"facility":"Local Institution - 0313","city":"Osaka","zip":"558-8558","country":"Japan","geoPoint":{"lat":34.69374,"lon":135.50218}},{"facility":"Local Institution - 0301","city":"Saga","zip":"849-8501","country":"Japan","geoPoint":{"lat":33.23333,"lon":130.3}},{"facility":"Local Institution - 0094","city":"Goyang-si","state":"Gyeonggido","zip":"10380","country":"Korea, Republic of","geoPoint":{"lat":37.65639,"lon":126.835}},{"facility":"Local Institution - 0088","city":"Seoul","state":"Seoul Teugbyeolsi","zip":"05505","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Local Institution - 0081","city":"Anyang","zip":"431-070","country":"Korea, Republic of","geoPoint":{"lat":37.3925,"lon":126.92694}},{"facility":"Local Institution - 0109","city":"Busan","zip":"49201","country":"Korea, Republic of","geoPoint":{"lat":35.10278,"lon":129.04028}},{"facility":"Local Institution - 0166","city":"Busan","zip":"49241","country":"Korea, Republic of","geoPoint":{"lat":35.10278,"lon":129.04028}},{"facility":"Local Institution - 0179","city":"Daegu","zip":"41944","country":"Korea, Republic of","geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Local Institution - 0102","city":"Daegu","zip":"42415","country":"Korea, Republic of","geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Local Institution","city":"Daegu","zip":"700-712","country":"Korea, Republic of","geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Local Institution - 0105","city":"Gwangju","zip":"61469","country":"Korea, Republic of","geoPoint":{"lat":35.15472,"lon":126.91556}},{"facility":"Local Institution - 0101","city":"Incheon","zip":"22332","country":"Korea, Republic of","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"Local Institution - 0153","city":"Seongnam-si","zip":"13620","country":"Korea, Republic of","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Local Institution - 0087","city":"Seoul","zip":"01830","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Local Institution - 0185","city":"Seoul","zip":"02447","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Local Institution - 0071","city":"Seoul","zip":"03080","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Local Institution - 0080","city":"Seoul","zip":"03722","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Local Institution - 0120","city":"Seoul","zip":"04763","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Local Institution - 0145","city":"Seoul","zip":"06273","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Local Institution - 0152","city":"Seoul","zip":"07061","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Local Institution - 0112","city":"Seoul","zip":"08308","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Local Institution - 0091","city":"Seoul","zip":"130-710","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Local Institution","city":"Ciudad de Mexico","state":"Distrito Federal","zip":"14080","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"Local Institution - 0398","city":"Mexico","state":"Distrito Federal","zip":"14269","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"Local Institution - 0396","city":"Guadalajara","state":"Jalisco","zip":"44670","country":"Mexico","geoPoint":{"lat":20.66682,"lon":-103.39182}},{"facility":"Local Institution - 0404","city":"Monterrey","state":"Nuevo LEON","zip":"64460","country":"Mexico","geoPoint":{"lat":25.67507,"lon":-100.31847}},{"facility":"Local Institution - 0394","city":"Culiacan","state":"Sinaloa","zip":"80020","country":"Mexico","geoPoint":{"lat":24.79032,"lon":-107.38782}},{"facility":"Local Institution - 0366","city":"Durango","zip":"34217","country":"Mexico","geoPoint":{"lat":24.02032,"lon":-104.65756}},{"facility":"Local Institution - 0368","city":"Bergen","zip":"5021","country":"Norway","geoPoint":{"lat":60.39299,"lon":5.32415}},{"facility":"Local Institution - 0383","city":"Grålum","zip":"1714","country":"Norway","geoPoint":{"lat":59.29048,"lon":11.06668}},{"facility":"Local Institution","city":"Kristiansand","zip":"4604","country":"Norway","geoPoint":{"lat":58.14671,"lon":7.9956}},{"facility":"Local Institution - 0130","city":"Lørenskog","zip":"1478","country":"Norway","geoPoint":{"lat":59.92625,"lon":10.95422}},{"facility":"Local Institution - 0408","city":"Oslo","zip":"0424","country":"Norway","geoPoint":{"lat":59.91273,"lon":10.74609}},{"facility":"Local Institution - 0330","city":"Stavanger","zip":"4068","country":"Norway","geoPoint":{"lat":58.97005,"lon":5.73332}},{"facility":"Local Institution - 0265","city":"Warszawa","state":"Mazowieckie","zip":"04-141","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Local Institution - 0350","city":"Bydgoszcz","zip":"85-094","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"Local Institution - 0216","city":"Chelm","zip":"22-100","country":"Poland","geoPoint":{"lat":51.14312,"lon":23.4716}},{"facility":"Local Institution - 0206","city":"Gdansk","zip":"80-803","country":"Poland","geoPoint":{"lat":54.35205,"lon":18.64637}},{"facility":"Local Institution - 0181","city":"Grodzisk Mazowieciki","zip":"05-825","country":"Poland"},{"facility":"Local Institution - 0253","city":"Katowice","zip":"40-635","country":"Poland","geoPoint":{"lat":50.25841,"lon":19.02754}},{"facility":"Local Institution","city":"Konskie","zip":"26-200","country":"Poland","geoPoint":{"lat":51.19166,"lon":20.40607}},{"facility":"Local Institution - 0197","city":"Lodz","zip":"93-113","country":"Poland","geoPoint":{"lat":51.75,"lon":19.46667}},{"facility":"Local Institution - 0198","city":"Olsztyn","zip":"10-561","country":"Poland","geoPoint":{"lat":53.77995,"lon":20.49416}},{"facility":"Local Institution - 0215","city":"Sandomierz","zip":"27-600","country":"Poland","geoPoint":{"lat":50.68265,"lon":21.74898}},{"facility":"Local Institution - 0183","city":"Skarzysko-Kamienna","zip":"26-110","country":"Poland","geoPoint":{"lat":51.11311,"lon":20.87162}},{"facility":"Local Institution - 0225","city":"Walcz","zip":"78-600","country":"Poland","geoPoint":{"lat":53.27787,"lon":16.47122}},{"facility":"Local Institution","city":"Warszawa","zip":"02-097","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Local Institution - 0214","city":"Warszawa","zip":"02-957","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Local Institution - 0212","city":"Wejherowo","zip":"84-200","country":"Poland","geoPoint":{"lat":54.60568,"lon":18.23559}},{"facility":"Local Institution - 0277","city":"Barnaul","zip":"656038","country":"Russian Federation","geoPoint":{"lat":53.36056,"lon":83.76361}},{"facility":"Local Institution - 0260","city":"Kemerovo","zip":"650002","country":"Russian Federation","geoPoint":{"lat":55.33333,"lon":86.08333}},{"facility":"Local Institution - 0306","city":"Moscow","zip":"117593","country":"Russian Federation","geoPoint":{"lat":55.75222,"lon":37.61556}},{"facility":"Local Institution","city":"Moscow","zip":"125367","country":"Russian Federation","geoPoint":{"lat":55.75222,"lon":37.61556}},{"facility":"Local Institution - 0268","city":"Novosibirsk","zip":"630087","country":"Russian Federation","geoPoint":{"lat":55.0415,"lon":82.9346}},{"facility":"Local Institution - 0202","city":"Smolensk","zip":"214018","country":"Russian Federation","geoPoint":{"lat":54.7818,"lon":32.0401}},{"facility":"Local Institution - 0356","city":"St. Petersburg","zip":"194354","country":"Russian Federation","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Local Institution","city":"Yaroslavl","zip":"150030","country":"Russian Federation","geoPoint":{"lat":57.62987,"lon":39.87368}},{"facility":"Local Institution - 0159","city":"Sabadell","state":"Barcelona","zip":"08208","country":"Spain","geoPoint":{"lat":41.54329,"lon":2.10942}},{"facility":"Local Institution - 0163","city":"Sant Joan Despi","state":"Barcelona","zip":"08970","country":"Spain","geoPoint":{"lat":41.36718,"lon":2.0574}},{"facility":"Local Institution - 0372","city":"León","state":"Castilla Y León","zip":"24071","country":"Spain","geoPoint":{"lat":42.60003,"lon":-5.57032}},{"facility":"Local Institution - 0141","city":"A Coruna","zip":"15006","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Local Institution - 0026","city":"Albacete","zip":"02006","country":"Spain","geoPoint":{"lat":38.99424,"lon":-1.85643}},{"facility":"Local Institution - 0052","city":"Badalona","zip":"08916","country":"Spain","geoPoint":{"lat":41.45004,"lon":2.24741}},{"facility":"Local Institution - 0012","city":"Barcelona","zip":"08003","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Local Institution - 0010","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Local Institution - 0027","city":"Barcelona","zip":"08036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Local Institution - 0385","city":"Córdoba","zip":"14004","country":"Spain","geoPoint":{"lat":37.89155,"lon":-4.77275}},{"facility":"Local Institution - 0426","city":"Girona","zip":"17007","country":"Spain","geoPoint":{"lat":41.98311,"lon":2.82493}},{"facility":"Local Institution - 0176","city":"L'Hospitalet de Llobregat","zip":"08907","country":"Spain","geoPoint":{"lat":41.35967,"lon":2.10028}},{"facility":"Local Institution - 0249","city":"Lleida","zip":"25008","country":"Spain","geoPoint":{"lat":41.61674,"lon":0.62218}},{"facility":"Local Institution - 0238","city":"Madrid","zip":"28007","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Local Institution - 0025","city":"Madrid","zip":"28034","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Local Institution - 0413","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Local Institution - 0384","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Local Institution - 0400","city":"San Sebastian","zip":"20014","country":"Spain","geoPoint":{"lat":43.31283,"lon":-1.97499}},{"facility":"Local Institution - 0425","city":"Santiago de Compostela","zip":"15706","country":"Spain","geoPoint":{"lat":42.88052,"lon":-8.54569}},{"facility":"Local Institution - 0158","city":"Sevilla","zip":"41009","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Local Institution - 0177","city":"Sevilla","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Local Institution - 0164","city":"Tarragona","zip":"43005","country":"Spain","geoPoint":{"lat":41.11667,"lon":1.25}},{"facility":"Local Institution - 0150","city":"Terrassa","zip":"08222","country":"Spain","geoPoint":{"lat":41.56667,"lon":2.01667}},{"facility":"Local Institution - 0147","city":"Valencia","zip":"46026","country":"Spain","geoPoint":{"lat":39.46975,"lon":-0.37739}},{"facility":"Local Institution - 0014","city":"Valladolid","zip":"47005","country":"Spain","geoPoint":{"lat":41.65518,"lon":-4.72372}},{"facility":"Local Institution - 0418","city":"Vigo","zip":"36312","country":"Spain","geoPoint":{"lat":42.23282,"lon":-8.72264}},{"facility":"Local Institution - 0128","city":"Malmö","state":"Skane Lan","zip":"SE-205 02","country":"Sweden","geoPoint":{"lat":55.60587,"lon":13.00073}},{"facility":"Local Institution - 0171","city":"Göteborg","zip":"SE-43146","country":"Sweden","geoPoint":{"lat":57.70716,"lon":11.96679}},{"facility":"Local Institution - 0191","city":"Hassleholm","zip":"28125","country":"Sweden","geoPoint":{"lat":56.15905,"lon":13.76638}},{"facility":"Local Institution - 0224","city":"Umea","zip":"901 87","country":"Sweden","geoPoint":{"lat":63.82842,"lon":20.25972}},{"facility":"Local Institution - 0132","city":"Uppsala","zip":"SE-752 37","country":"Sweden","geoPoint":{"lat":59.85882,"lon":17.63889}},{"facility":"Local Institution - 0118","city":"Basel","state":"Basel-Stadt (de)","zip":"4031","country":"Switzerland","geoPoint":{"lat":47.55839,"lon":7.57327}},{"facility":"Local Institution - 0115","city":"Bern","state":"Bern (de)","zip":"3010","country":"Switzerland","geoPoint":{"lat":46.94809,"lon":7.44744}},{"facility":"Local Institution - 0162","city":"Aarau","zip":"5001","country":"Switzerland","geoPoint":{"lat":47.39254,"lon":8.04422}},{"facility":"Local Institution - 0203","city":"Geneve","zip":"1205","country":"Switzerland","geoPoint":{"lat":46.20222,"lon":6.14569}},{"facility":"Local Institution - 0201","city":"Lausanne","zip":"1011","country":"Switzerland","geoPoint":{"lat":46.516,"lon":6.63282}},{"facility":"Local Institution","city":"Zurich","zip":"8032","country":"Switzerland","geoPoint":{"lat":47.36667,"lon":8.54999}},{"facility":"Local Institution - 0222","city":"Canterbury","state":"Kent","zip":"CT1 3NG","country":"United Kingdom","geoPoint":{"lat":51.27904,"lon":1.07992}},{"facility":"Local Institution - 0140","city":"Aberdeen","zip":"AB25 2ZD","country":"United Kingdom","geoPoint":{"lat":57.14369,"lon":-2.09814}},{"facility":"Local Institution","city":"Ashford","zip":"TN24 0LZ","country":"United Kingdom","geoPoint":{"lat":51.14648,"lon":0.87376}},{"facility":"Local Institution - 0157","city":"Bath","zip":"BA1 3NG","country":"United Kingdom","geoPoint":{"lat":51.3751,"lon":-2.36172}},{"facility":"Local Institution - 0089","city":"Chester","zip":"CH2 1UL","country":"United Kingdom","geoPoint":{"lat":53.1905,"lon":-2.89189}},{"facility":"Local Institution - 0221","city":"Edinburgh","zip":"EH16 4SA","country":"United Kingdom","geoPoint":{"lat":55.95206,"lon":-3.19648}},{"facility":"Local Institution - 0096","city":"Glasgow","zip":"G51 4TF","country":"United Kingdom","geoPoint":{"lat":55.86515,"lon":-4.25763}},{"facility":"Local Institution - 0361","city":"Lancashire","zip":"BL9 7TD","country":"United Kingdom"},{"facility":"Local Institution","city":"London","zip":"SE5 9RF","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Local Institution","city":"London","zip":"W1T 7HA","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Local Institution - 0303","city":"Luton","zip":"LU4 0DZ","country":"United Kingdom","geoPoint":{"lat":51.87967,"lon":-0.41748}},{"facility":"Local Institution","city":"Nottingham","zip":"NG5 1PB","country":"United Kingdom","geoPoint":{"lat":52.9536,"lon":-1.15047}},{"facility":"Local Institution - 0431","city":"Salford","zip":"M6 8HD","country":"United Kingdom","geoPoint":{"lat":53.48771,"lon":-2.29042}},{"facility":"Local Institution - 0414","city":"Sheffield","zip":"S10 2JF","country":"United Kingdom","geoPoint":{"lat":53.38297,"lon":-1.4659}},{"facility":"Local Institution - 0307","city":"Staffordshire","zip":"ST4 6QG","country":"United Kingdom"}]},"referencesModule":{"seeAlsoLinks":[{"label":"BMS Clinical Trial Information","url":"https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"},{"label":"BMS Clinical Trial Patient Recruiting","url":"https://www.BMSStudyConnect.com"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"FG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"FG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"FG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"FG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"FG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"FG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"FG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"periods":[{"title":"Randomization","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"691"},{"groupId":"FG001","numSubjects":"328"},{"groupId":"FG002","numSubjects":"318"},{"groupId":"FG003","numSubjects":"328"},{"groupId":"FG004","numSubjects":"310"},{"groupId":"FG005","numSubjects":"351"},{"groupId":"FG006","numSubjects":"22"},{"groupId":"FG007","numSubjects":"18"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"682"},{"groupId":"FG001","numSubjects":"324"},{"groupId":"FG002","numSubjects":"313"},{"groupId":"FG003","numSubjects":"325"},{"groupId":"FG004","numSubjects":"306"},{"groupId":"FG005","numSubjects":"345"},{"groupId":"FG006","numSubjects":"22"},{"groupId":"FG007","numSubjects":"17"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"6"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Other reasons","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}]},{"type":"Participant no longer meets study criteria","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1"}]},{"type":"Participant request to discontinue study treatment","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}]},{"type":"Participant withdrew consent","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}]}]},{"title":"Treatment","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"682"},{"groupId":"FG001","comment":"1 participant was randomized to Milvexian 200 mg BID, but received Milvexian 25 mg QD.","numSubjects":"325"},{"groupId":"FG002","numSubjects":"313"},{"groupId":"FG003","numSubjects":"325"},{"groupId":"FG004","numSubjects":"306"},{"groupId":"FG005","comment":"1 participant was randomized to Milvexian 200 mg BID, but received Milvexian 25 mg QD.","numSubjects":"344"},{"groupId":"FG006","numSubjects":"22"},{"groupId":"FG007","numSubjects":"17"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"529"},{"groupId":"FG001","numSubjects":"260"},{"groupId":"FG002","numSubjects":"242"},{"groupId":"FG003","numSubjects":"251"},{"groupId":"FG004","numSubjects":"230"},{"groupId":"FG005","numSubjects":"240"},{"groupId":"FG006","numSubjects":"15"},{"groupId":"FG007","numSubjects":"14"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"153"},{"groupId":"FG001","numSubjects":"65"},{"groupId":"FG002","numSubjects":"71"},{"groupId":"FG003","numSubjects":"74"},{"groupId":"FG004","numSubjects":"76"},{"groupId":"FG005","numSubjects":"104"},{"groupId":"FG006","numSubjects":"7"},{"groupId":"FG007","numSubjects":"3"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"82"},{"groupId":"FG001","numSubjects":"44"},{"groupId":"FG002","numSubjects":"47"},{"groupId":"FG003","numSubjects":"46"},{"groupId":"FG004","numSubjects":"50"},{"groupId":"FG005","numSubjects":"77"},{"groupId":"FG006","numSubjects":"5"},{"groupId":"FG007","numSubjects":"2"}]},{"type":"Participant request to discontinue treatment","reasons":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"14"},{"groupId":"FG005","numSubjects":"15"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1"}]},{"type":"Participant withdrew consent","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}]},{"type":"Poor/Non compliance","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}]},{"type":"Participant no longer meets study criteria","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"0"}]},{"type":"Other reasons","reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"BG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"BG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"BG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"BG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"BG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"BG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"BG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"BG008","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"691"},{"groupId":"BG001","value":"328"},{"groupId":"BG002","value":"318"},{"groupId":"BG003","value":"328"},{"groupId":"BG004","value":"310"},{"groupId":"BG005","value":"351"},{"groupId":"BG006","value":"22"},{"groupId":"BG007","value":"18"},{"groupId":"BG008","value":"2366"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"69.1","spread":"10.58"},{"groupId":"BG001","value":"70.9","spread":"10.66"},{"groupId":"BG002","value":"70.1","spread":"11.34"},{"groupId":"BG003","value":"69.3","spread":"10.69"},{"groupId":"BG004","value":"69.7","spread":"10.59"},{"groupId":"BG005","value":"69.5","spread":"11.11"},{"groupId":"BG006","value":"65.7","spread":"10.64"},{"groupId":"BG007","value":"65.4","spread":"11.65"},{"groupId":"BG008","value":"69.6","spread":"10.81"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"254"},{"groupId":"BG001","value":"109"},{"groupId":"BG002","value":"118"},{"groupId":"BG003","value":"121"},{"groupId":"BG004","value":"112"},{"groupId":"BG005","value":"128"},{"groupId":"BG006","value":"7"},{"groupId":"BG007","value":"10"},{"groupId":"BG008","value":"859"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"437"},{"groupId":"BG001","value":"219"},{"groupId":"BG002","value":"200"},{"groupId":"BG003","value":"207"},{"groupId":"BG004","value":"198"},{"groupId":"BG005","value":"223"},{"groupId":"BG006","value":"15"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"1507"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"22"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"62"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"23"},{"groupId":"BG004","value":"29"},{"groupId":"BG005","value":"27"},{"groupId":"BG006","value":"7"},{"groupId":"BG007","value":"7"},{"groupId":"BG008","value":"197"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"619"},{"groupId":"BG001","value":"304"},{"groupId":"BG002","value":"294"},{"groupId":"BG003","value":"304"},{"groupId":"BG004","value":"279"},{"groupId":"BG005","value":"323"},{"groupId":"BG006","value":"14"},{"groupId":"BG007","value":"10"},{"groupId":"BG008","value":"2147"}]}]}]},{"title":"Race/Ethnicity, Customized","description":"Race","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"549"},{"groupId":"BG001","value":"257"},{"groupId":"BG002","value":"246"},{"groupId":"BG003","value":"260"},{"groupId":"BG004","value":"251"},{"groupId":"BG005","value":"288"},{"groupId":"BG006","value":"18"},{"groupId":"BG007","value":"15"},{"groupId":"BG008","value":"1884"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"48"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"17"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"109"}]}]},{"title":"Native Hawaiian or Other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"2"}]}]},{"title":"Asian Indian","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"6"}]}]},{"title":"Chinese","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"}]}]},{"title":"Japanese","categories":[{"measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"40"},{"groupId":"BG003","value":"41"},{"groupId":"BG004","value":"39"},{"groupId":"BG005","value":"40"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"290"}]}]},{"title":"Malay","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"}]}]},{"title":"Asian Other","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"24"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90","description":"Model based assessment estimate for composite event is a customized statistical analysis called MCP-MOD (Multiple Comparison Procedures, MODel) estimation, which is used to check for dose-response relationship. 95% confidence interval (CI) for composite event based on bootstrap (10000 samples).","populationDescription":"All randomized participants who experienced a new ischemic stroke by day 90, or an evaluable day 90 MRI regardless of when the MRI was collected. Dose -response model-based endpoint that was pre-specified for data to be collected only in the Placebo, 25 mg QD, and BID dose regimens.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From randomization to up to 90 days after randomization","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"625"},{"groupId":"OG001","value":"308"},{"groupId":"OG002","value":"287"},{"groupId":"OG003","value":"306"},{"groupId":"OG004","value":"277"},{"groupId":"OG005","value":"317"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","lowerLimit":"14.2","upperLimit":"19.4"},{"groupId":"OG001","value":"16.7","lowerLimit":"14.4","upperLimit":"19.0"},{"groupId":"OG002","value":"16.6","lowerLimit":"14.5","upperLimit":"18.7"},{"groupId":"OG003","value":"15.6","lowerLimit":"13.6","upperLimit":"17.9"},{"groupId":"OG004","value":"15.4","lowerLimit":"13.0","upperLimit":"18.0"},{"groupId":"OG005","value":"15.3","lowerLimit":"12.3","upperLimit":"20.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Milvexian 25 mg QD over Placebo","nonInferiorityType":"SUPERIORITY","statisticalMethod":"MCP-MOD","statisticalComment":"Multiple Comparison Procedures, MODel","paramType":"Relative Risk (RR)","paramValue":"0.99","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.87","ciUpperLimit":"1.10","estimateComment":"95% confidence interval (CI) for composite event based on bootstrap (10000 samples)"},{"groupIds":["OG000","OG002"],"groupDescription":"Milvexian 25 mg BID over Placebo","nonInferiorityType":"SUPERIORITY","statisticalMethod":"MCP-MOD","statisticalComment":"Multiple Comparison Procedures, MODel","paramType":"Relative Risk (RR)","paramValue":"0.99","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.83","ciUpperLimit":"1.15","estimateComment":"95% confidence interval (CI) for composite event based on bootstrap (10000 samples)"},{"groupIds":["OG000","OG003"],"groupDescription":"Milvexian 50 mg BID over Placebo","nonInferiorityType":"SUPERIORITY","statisticalMethod":"MCP-MOD","statisticalComment":"Multiple Comparison Procedures, MODel","paramType":"Relative Risk (RR)","paramValue":"0.93","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.76","ciUpperLimit":"1.16","estimateComment":"95% confidence interval (CI) for composite event based on bootstrap (10000 samples)"},{"groupIds":["OG000","OG004"],"groupDescription":"Milvexian 100 mg BID over Placebo","nonInferiorityType":"SUPERIORITY","statisticalMethod":"MCP-MOD","statisticalComment":"Multiple Comparison Procedures, MODel","paramType":"Relative Risk (RR)","paramValue":"0.92","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.73","ciUpperLimit":"1.18","estimateComment":"95% confidence interval (CI) for composite event based on bootstrap (10000 samples)"},{"groupIds":["OG000","OG005"],"groupDescription":"Milvexian 200 mg BID over Placebo","nonInferiorityType":"SUPERIORITY","statisticalMethod":"MCP-MOD","statisticalComment":"Multiple Comparison Procedures, MODel","paramType":"Relative Risk (RR)","paramValue":"0.91","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.69","ciUpperLimit":"1.31","estimateComment":"95% confidence interval (CI) for composite event based on bootstrap (10000 samples)"}]},{"type":"SECONDARY","title":"Percent of Participants With Major Bleeding According to BARC Type 3 and 5","description":"Percent of participants with major bleeding based on the Bleeding Academic Research Consortium (BARC) Types 3 and 5 definitions. BARC bleeding types:\n\n3a = Overt bleeding plus hemoglobin drop of 3 to \\< 5 g/dL transfusion with overt bleeding 3b = Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents 3c = Intracranial hemorrhage, 5a = Probable fatal bleeding 5b = Definite fatal bleeding","populationDescription":"All treated participants","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From first dose to up to 107 days after first dose","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"682"},{"groupId":"OG001","value":"325"},{"groupId":"OG002","value":"313"},{"groupId":"OG003","value":"325"},{"groupId":"OG004","value":"306"},{"groupId":"OG005","value":"344"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.2","upperLimit":"1.5"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.1","upperLimit":"2.2"},{"groupId":"OG002","value":"0.6","lowerLimit":"0.1","upperLimit":"2.3"},{"groupId":"OG003","value":"1.5","lowerLimit":"0.5","upperLimit":"3.6"},{"groupId":"OG004","value":"1.6","lowerLimit":"0.5","upperLimit":"3.8"},{"groupId":"OG005","value":"1.5","lowerLimit":"0.5","upperLimit":"3.4"},{"groupId":"OG006","value":"0","lowerLimit":"0","upperLimit":"15.4"},{"groupId":"OG007","value":"0","lowerLimit":"0","upperLimit":"19.5"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Bleeding Based on BARC Types 1-5","description":"Number of participants with bleeding based on Bleeding Academic Research Consortium (BARC) Type 1 to 5. BARC bleeding types: 0=No bleeding. 1=Not actionable bleeding. 2=Overt, actionable sign of hemorrhage requiring nonsurgical, medical intervention by a health-care professional, leading to hospitalization or increased level of care, or prompting evaluation. 3a=Overt bleeding plus hemoglobin drop of 3 to \\< 5 g/dL. 3b=Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention; bleeding requiring IV vasoactive agents. 3c=Intracranial hemorrhage; intraocular bleed compromising vision. 4=CABG-related bleeding, perioperative intracranial bleeding within 48 hours, reoperation after closure of sternotomy to control bleeding, transfusion of ≥5 U whole blood or packed red blood cells within a 48-hour period, chest tube output more than or equal to 2L within a 24-hour period. 5a=Probable fatal bleeding. 5b=Definite fatal bleeding.","populationDescription":"All treated participants","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to up to 107 days after first dose","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"682"},{"groupId":"OG001","value":"325"},{"groupId":"OG002","value":"313"},{"groupId":"OG003","value":"325"},{"groupId":"OG004","value":"306"},{"groupId":"OG005","value":"344"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"17"}]}],"classes":[{"title":"Type 1","categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"2"}]}]},{"title":"Type 2","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"}]}]},{"title":"Type 3A","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"Type 3B","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"Type 3C","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"Type 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"Type 5A","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"Type 5B","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Bleeding Based on ISTH-Defined Criteria","description":"Number of participants with bleeding based on International Society on Thrombosis and Hemostasis (ISTH). ISTH Bleeding Types: 1) Fatal bleeding and/or 2) Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome and/or 3) Bleeding causing a fall in hemoglobin level of ≥2 g/dL, or leading to transfusion of ≥2 units of whole blood or red cells.","populationDescription":"All treated participants","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to up to 107 days after first dose","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"682"},{"groupId":"OG001","value":"325"},{"groupId":"OG002","value":"313"},{"groupId":"OG003","value":"325"},{"groupId":"OG004","value":"306"},{"groupId":"OG005","value":"344"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"17"}]}],"classes":[{"title":"Major","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"Clinically Relevant Non-Major (CRNM)","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"}]}]},{"title":"Major or CRNM","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"}]}]},{"title":"Minor Bleed","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Bleeding Based on PLATO-Defined Criteria","description":"Number of participants with bleeding based on Platelet Inhibition and Patient Outcomes (PLATO) defined criteria. PLATO bleeding definitions:\n\n1. Major Life-threatening: Fatal, Intracranial, Intrapericardial with cardiac tamponade, Resulting in hypovolemic shock or severe hypotension that requires pressors or surgery, Clinically overt or apparent bleeding associated with decrease in hemoglobin \\>5 g/dL, Requiring transfusion of ≥4 U whole blood or packed red blood cells (PRBCs)\n2. Other Major: Significantly disabling (eg, intraocular with permanent vision loss), Associated drop in hemoglobin of 3 to 5 g/dL, Requiring transfusion of 2 to 3 U whole blood or PRBCs\n3. Any Major: Any one of the above criteria\n4. Minor: Bleeding that does not meet criteria for PLATO Major bleeding, and requiring medical intervention","populationDescription":"All treated participants","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to up to 107 days after first dose","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"682"},{"groupId":"OG001","value":"325"},{"groupId":"OG002","value":"313"},{"groupId":"OG003","value":"325"},{"groupId":"OG004","value":"306"},{"groupId":"OG005","value":"344"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"17"}]}],"classes":[{"title":"MAJOR LIFE-THREATENING","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"OTHER MAJOR BLEEDING","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"ANY MAJOR","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"MINOR","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"}]}]},{"title":"MINIMAL","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"21"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"2"}]}]}]},{"type":"SECONDARY","title":"Percent of Participants With Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90","description":"Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90.","populationDescription":"All randomized participants who experienced a new ischemic stroke by day 90, or an evaluable day 90 MRI regardless of when the MRI was collected.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"From randomization to up to 90 days after randomization","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"625"},{"groupId":"OG001","value":"308"},{"groupId":"OG002","value":"287"},{"groupId":"OG003","value":"306"},{"groupId":"OG004","value":"277"},{"groupId":"OG005","value":"317"},{"groupId":"OG006","value":"21"},{"groupId":"OG007","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6"},{"groupId":"OG001","value":"16.2"},{"groupId":"OG002","value":"18.5"},{"groupId":"OG003","value":"14.1"},{"groupId":"OG004","value":"14.8"},{"groupId":"OG005","value":"16.4"},{"groupId":"OG006","value":"19.0"},{"groupId":"OG007","value":"18.8"}]}]}]},{"type":"SECONDARY","title":"Composite of Percent of Participants With New Ischemic Stroke, MI and All Cause Death","description":"Composite of percent of participants of new ischemic stroke, (Myocardial Infarction) MI and all cause death.","populationDescription":"All randomized participants","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From randomization to up to 90 days after randomization","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"691"},{"groupId":"OG001","value":"328"},{"groupId":"OG002","value":"318"},{"groupId":"OG003","value":"328"},{"groupId":"OG004","value":"310"},{"groupId":"OG005","value":"351"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"18"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","lowerLimit":"4.3","upperLimit":"7.9"},{"groupId":"OG001","value":"5.2","lowerLimit":"2.8","upperLimit":"7.6"},{"groupId":"OG002","value":"4.7","lowerLimit":"2.4","upperLimit":"7.0"},{"groupId":"OG003","value":"4.9","lowerLimit":"2.5","upperLimit":"7.2"},{"groupId":"OG004","value":"5.2","lowerLimit":"2.7","upperLimit":"7.6"},{"groupId":"OG005","value":"9.4","lowerLimit":"6.3","upperLimit":"12.5"},{"groupId":"OG006","value":"18.2","lowerLimit":"2.1","upperLimit":"34.3"},{"groupId":"OG007","value":"5.6","lowerLimit":"0","upperLimit":"16.1"}]}]}]},{"type":"SECONDARY","title":"National Institutes of Health Stroke Scale (NIHSS)","description":"The NIHSS is an 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. The score for each ability is a number between 0 and 4, 0 being normal functioning and 4 being completely impaired. The patient's NIHSS score is calculated by adding the number for each element of the scale; 42 is the highest score possible. In the NIHSS, the higher the score, the more impaired a stroke participant is.","populationDescription":"All randomized participants with a complete NIHSS assessment","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"At baseline, on Days 21 and 90, and at the time of a new stroke event","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"684"},{"groupId":"OG001","value":"324"},{"groupId":"OG002","value":"311"},{"groupId":"OG003","value":"326"},{"groupId":"OG004","value":"305"},{"groupId":"OG005","value":"348"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"17"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"684"},{"groupId":"OG001","value":"324"},{"groupId":"OG002","value":"311"},{"groupId":"OG003","value":"326"},{"groupId":"OG004","value":"305"},{"groupId":"OG005","value":"348"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"1.87"},{"groupId":"OG001","value":"1.7","spread":"1.68"},{"groupId":"OG002","value":"1.6","spread":"1.73"},{"groupId":"OG003","value":"1.6","spread":"1.79"},{"groupId":"OG004","value":"1.8","spread":"1.81"},{"groupId":"OG005","value":"1.6","spread":"1.79"},{"groupId":"OG006","value":"1.1","spread":"1.44"},{"groupId":"OG007","value":"2.0","spread":"1.70"}]}]},{"title":"Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"624"},{"groupId":"OG001","value":"294"},{"groupId":"OG002","value":"280"},{"groupId":"OG003","value":"301"},{"groupId":"OG004","value":"271"},{"groupId":"OG005","value":"314"},{"groupId":"OG006","value":"18"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"2.11"},{"groupId":"OG001","value":"0.8","spread":"1.35"},{"groupId":"OG002","value":"0.8","spread":"1.43"},{"groupId":"OG003","value":"0.8","spread":"1.58"},{"groupId":"OG004","value":"0.8","spread":"1.48"},{"groupId":"OG005","value":"0.9","spread":"1.88"},{"groupId":"OG006","value":"0.8","spread":"1.90"},{"groupId":"OG007","value":"0.9","spread":"1.39"}]}]},{"title":"Day 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"552"},{"groupId":"OG001","value":"263"},{"groupId":"OG002","value":"251"},{"groupId":"OG003","value":"259"},{"groupId":"OG004","value":"238"},{"groupId":"OG005","value":"256"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.40"},{"groupId":"OG001","value":"0.6","spread":"1.06"},{"groupId":"OG002","value":"0.6","spread":"1.51"},{"groupId":"OG003","value":"0.6","spread":"1.14"},{"groupId":"OG004","value":"0.6","spread":"1.32"},{"groupId":"OG005","value":"0.6","spread":"1.29"},{"groupId":"OG006","value":"0.3","spread":"0.72"},{"groupId":"OG007","value":"0.6","spread":"1.45"}]}]},{"title":"First recurrent stroke","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"20"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"5.01"},{"groupId":"OG001","value":"4.6","spread":"6.79"},{"groupId":"OG002","value":"5.4","spread":"3.17"},{"groupId":"OG003","value":"4.6","spread":"4.30"},{"groupId":"OG004","value":"7.1","spread":"4.68"},{"groupId":"OG005","value":"4.4","spread":"4.60"},{"groupId":"OG006","value":"5.3","spread":"3.06"},{"groupId":"OG007","value":"1.0","spread":"NA","comment":"Insufficient number of participants with events"}]}]}]},{"type":"SECONDARY","title":"Modified Rankin Scale (mRS)","description":"The Modified Rankin Score (mRS) is a 6-point disability scale with possible scores ranging from 0 to 6.\n\n0 = No symptoms at all\n\n1. = No significant disability despite symptoms; able to carry out all usual duties and activities\n2. = Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance\n3. = Moderate disability; requiring some help, but able to walk without assistance\n4. = Moderately severe disability; unable to walk and attend to bodily needs without assistance\n5. = Severe disability; bedridden, incontinent and requiring constant nursing care and attention\n6. = Dead","populationDescription":"All randomized participants with a complete mRS assessment","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"At baseline, on Days 21 and 90, and at the time of a new stroke event","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"688"},{"groupId":"OG001","value":"326"},{"groupId":"OG002","value":"314"},{"groupId":"OG003","value":"328"},{"groupId":"OG004","value":"309"},{"groupId":"OG005","value":"349"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"17"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"688"},{"groupId":"OG001","value":"326"},{"groupId":"OG002","value":"314"},{"groupId":"OG003","value":"328"},{"groupId":"OG004","value":"309"},{"groupId":"OG005","value":"349"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.87"},{"groupId":"OG001","value":"0.6","spread":"0.95"},{"groupId":"OG002","value":"0.6","spread":"0.96"},{"groupId":"OG003","value":"0.5","spread":"0.86"},{"groupId":"OG004","value":"0.5","spread":"0.89"},{"groupId":"OG005","value":"0.6","spread":"0.95"},{"groupId":"OG006","value":"0.2","spread":"0.53"},{"groupId":"OG007","value":"0.7","spread":"0.99"}]}]},{"title":"Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"630"},{"groupId":"OG001","value":"301"},{"groupId":"OG002","value":"287"},{"groupId":"OG003","value":"306"},{"groupId":"OG004","value":"279"},{"groupId":"OG005","value":"316"},{"groupId":"OG006","value":"17"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.18"},{"groupId":"OG001","value":"1.0","spread":"1.13"},{"groupId":"OG002","value":"0.9","spread":"1.15"},{"groupId":"OG003","value":"0.9","spread":"1.15"},{"groupId":"OG004","value":"1.0","spread":"1.17"},{"groupId":"OG005","value":"0.9","spread":"1.19"},{"groupId":"OG006","value":"0.9","spread":"1.27"},{"groupId":"OG007","value":"1.3","spread":"1.14"}]}]},{"title":"Day 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"562"},{"groupId":"OG001","value":"269"},{"groupId":"OG002","value":"257"},{"groupId":"OG003","value":"265"},{"groupId":"OG004","value":"245"},{"groupId":"OG005","value":"259"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.04"},{"groupId":"OG001","value":"0.8","spread":"1.04"},{"groupId":"OG002","value":"0.8","spread":"1.07"},{"groupId":"OG003","value":"0.7","spread":"1.01"},{"groupId":"OG004","value":"0.7","spread":"1.01"},{"groupId":"OG005","value":"0.8","spread":"1.05"},{"groupId":"OG006","value":"0.6","spread":"1.05"},{"groupId":"OG007","value":"1.0","spread":"1.11"}]}]},{"title":"First recurrent stroke","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"1.60"},{"groupId":"OG001","value":"2.7","spread":"1.03"},{"groupId":"OG002","value":"2.6","spread":"1.35"},{"groupId":"OG003","value":"2.3","spread":"1.62"},{"groupId":"OG004","value":"2.9","spread":"1.64"},{"groupId":"OG005","value":"1.8","spread":"1.72"},{"groupId":"OG006","value":"2.0","spread":"0.00"},{"groupId":"OG007","value":"1.0","spread":"NA","comment":"Insufficient number of participants with events"}]}]}]},{"type":"SECONDARY","title":"Montreal Cognitive Assessment (MoCA)","description":"The Montreal Cognitive Assessment (MoCA) is a survey with a summed score. MoCA score ranges between a lowest score of 0 to a highest score of 30. A score of:\n\n* ≥26 points: indicates normal cognitive function\n* 18-25 points: Mild cognitive impairment\n* 10-17 points: Moderate cognitive impairment\n* fewer than 10 points: Severe cognitive impairment","populationDescription":"All randomized participants with a complete MoCA assessment","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"At baseline, on Days 21 and 90, and at the time of a new stroke event","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"541"},{"groupId":"OG001","value":"257"},{"groupId":"OG002","value":"235"},{"groupId":"OG003","value":"257"},{"groupId":"OG004","value":"235"},{"groupId":"OG005","value":"276"},{"groupId":"OG006","value":"17"},{"groupId":"OG007","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"541"},{"groupId":"OG001","value":"257"},{"groupId":"OG002","value":"235"},{"groupId":"OG003","value":"257"},{"groupId":"OG004","value":"235"},{"groupId":"OG005","value":"276"},{"groupId":"OG006","value":"17"},{"groupId":"OG007","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":"5.06"},{"groupId":"OG001","value":"21.6","spread":"5.59"},{"groupId":"OG002","value":"22.0","spread":"5.18"},{"groupId":"OG003","value":"22.5","spread":"4.82"},{"groupId":"OG004","value":"22.4","spread":"5.04"},{"groupId":"OG005","value":"22.1","spread":"5.31"},{"groupId":"OG006","value":"24.4","spread":"3.84"},{"groupId":"OG007","value":"22.0","spread":"4.59"}]}]},{"title":"Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"},{"groupId":"OG001","value":"231"},{"groupId":"OG002","value":"206"},{"groupId":"OG003","value":"236"},{"groupId":"OG004","value":"211"},{"groupId":"OG005","value":"251"},{"groupId":"OG006","value":"15"},{"groupId":"OG007","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":"4.77"},{"groupId":"OG001","value":"23.9","spread":"5.01"},{"groupId":"OG002","value":"24.0","spread":"4.70"},{"groupId":"OG003","value":"24.3","spread":"4.57"},{"groupId":"OG004","value":"23.6","spread":"4.48"},{"groupId":"OG005","value":"24.0","spread":"4.96"},{"groupId":"OG006","value":"26.4","spread":"2.61"},{"groupId":"OG007","value":"24.1","spread":"4.70"}]}]},{"title":"Day 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"435"},{"groupId":"OG001","value":"208"},{"groupId":"OG002","value":"183"},{"groupId":"OG003","value":"209"},{"groupId":"OG004","value":"180"},{"groupId":"OG005","value":"210"},{"groupId":"OG006","value":"15"},{"groupId":"OG007","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":"4.54"},{"groupId":"OG001","value":"24.0","spread":"4.69"},{"groupId":"OG002","value":"24.2","spread":"4.80"},{"groupId":"OG003","value":"24.4","spread":"4.48"},{"groupId":"OG004","value":"24.5","spread":"4.36"},{"groupId":"OG005","value":"24.2","spread":"5.05"},{"groupId":"OG006","value":"25.0","spread":"4.72"},{"groupId":"OG007","value":"26.4","spread":"1.69"}]}]},{"title":"First recurrent stroke","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.2","spread":"6.63"},{"groupId":"OG001","value":"17.3","spread":"6.11"},{"groupId":"OG002","value":"25.3","spread":"2.31"},{"groupId":"OG003","value":"19.0","spread":"8.49"},{"groupId":"OG004","value":"3.0","spread":"NA","comment":"Insufficient number of participants with events"},{"groupId":"OG005","value":"23.1","spread":"7.08"},{"groupId":"OG006","value":"11.0","spread":"NA","comment":"Insufficient number of participants with events"},{"groupId":"OG007","value":"22.0","spread":"NA","comment":"Insufficient number of participants with events"}]}]}]},{"type":"SECONDARY","title":"Digit Symbol Substitution Test (DSST)","description":"The Descriptive Summary of the Digit Symbol Substitution Test (DSST) is a scale item, with a lowest score of 0 and highest total score of 135. Higher score indicates better cognitive functioning.","populationDescription":"All randomized participants with a complete DSST assessment","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"At baseline, on Days 21 and 90, and at the time of a new stroke event","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"493"},{"groupId":"OG001","value":"238"},{"groupId":"OG002","value":"209"},{"groupId":"OG003","value":"234"},{"groupId":"OG004","value":"220"},{"groupId":"OG005","value":"257"},{"groupId":"OG006","value":"17"},{"groupId":"OG007","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"493"},{"groupId":"OG001","value":"238"},{"groupId":"OG002","value":"209"},{"groupId":"OG003","value":"234"},{"groupId":"OG004","value":"220"},{"groupId":"OG005","value":"257"},{"groupId":"OG006","value":"17"},{"groupId":"OG007","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.9","spread":"22.36"},{"groupId":"OG001","value":"31.2","spread":"18.87"},{"groupId":"OG002","value":"32.9","spread":"22.89"},{"groupId":"OG003","value":"37.2","spread":"25.67"},{"groupId":"OG004","value":"33.7","spread":"21.89"},{"groupId":"OG005","value":"31.7","spread":"19.15"},{"groupId":"OG006","value":"47.1","spread":"29.34"},{"groupId":"OG007","value":"29.2","spread":"18.16"}]}]},{"title":"Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"443"},{"groupId":"OG001","value":"213"},{"groupId":"OG002","value":"183"},{"groupId":"OG003","value":"213"},{"groupId":"OG004","value":"194"},{"groupId":"OG005","value":"228"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41.2","spread":"22.14"},{"groupId":"OG001","value":"38.9","spread":"19.27"},{"groupId":"OG002","value":"40.2","spread":"21.60"},{"groupId":"OG003","value":"45.1","spread":"25.77"},{"groupId":"OG004","value":"41.2","spread":"22.87"},{"groupId":"OG005","value":"39.1","spread":"21.35"},{"groupId":"OG006","value":"54.6","spread":"32.73"},{"groupId":"OG007","value":"37.1","spread":"20.13"}]}]},{"title":"Day 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"394"},{"groupId":"OG001","value":"191"},{"groupId":"OG002","value":"160"},{"groupId":"OG003","value":"186"},{"groupId":"OG004","value":"166"},{"groupId":"OG005","value":"192"},{"groupId":"OG006","value":"15"},{"groupId":"OG007","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42.8","spread":"21.18"},{"groupId":"OG001","value":"41.7","spread":"21.66"},{"groupId":"OG002","value":"41.3","spread":"20.29"},{"groupId":"OG003","value":"45.2","spread":"21.86"},{"groupId":"OG004","value":"45.5","spread":"23.44"},{"groupId":"OG005","value":"41.4","spread":"21.97"},{"groupId":"OG006","value":"47.5","spread":"27.48"},{"groupId":"OG007","value":"40.7","spread":"17.46"}]}]},{"title":"First recurrent stroke","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.3","spread":"13.56"},{"groupId":"OG001","value":"28.0","spread":"20.95"},{"groupId":"OG002","value":"42.0","spread":"4.36"},{"groupId":"OG003","value":"40.5","spread":"2.12"},{"groupId":"OG004","value":"23.0","spread":"NA","comment":"Insufficient number of participants with events"},{"groupId":"OG005","value":"27.5","spread":"16.96"},{"groupId":"OG006","value":"9.0","spread":"NA","comment":"Insufficient number of participants with events"},{"groupId":"OG007","value":"47.0","spread":"NA","comment":"Insufficient number of participants with events"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs)","description":"AE: include all non-serious adverse events with onset on or after first dose date and within 2 days after the last dose of study treatment.","populationDescription":"All treated participants","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to 2 days after last dose of study therapy (up to approximately 107 days)","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"682"},{"groupId":"OG001","value":"325"},{"groupId":"OG002","value":"313"},{"groupId":"OG003","value":"325"},{"groupId":"OG004","value":"306"},{"groupId":"OG005","value":"344"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"399"},{"groupId":"OG001","value":"190"},{"groupId":"OG002","value":"186"},{"groupId":"OG003","value":"192"},{"groupId":"OG004","value":"193"},{"groupId":"OG005","value":"211"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"13"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Significant Vital Sign Abnormalities","description":"Number of participants with clinically significant vital sign abnormalities. Vital signs included heart rate and diastolic and systolic blood pressure.","populationDescription":"All treated participants","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to up to 90 days after first dose","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"682"},{"groupId":"OG001","value":"325"},{"groupId":"OG002","value":"313"},{"groupId":"OG003","value":"325"},{"groupId":"OG004","value":"306"},{"groupId":"OG005","value":"344"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Significant Physical Examination Abnormalities","description":"Number of participants with clinically significant physical examination abnormalities.","populationDescription":"All treated participants","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to up to 90 days after first dose","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"682"},{"groupId":"OG001","value":"325"},{"groupId":"OG002","value":"313"},{"groupId":"OG003","value":"325"},{"groupId":"OG004","value":"306"},{"groupId":"OG005","value":"344"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities","description":"Number of participants with clinically significant ECG abnormalities.","populationDescription":"All treated participants","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to up to 90 days after first dose","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"682"},{"groupId":"OG001","value":"325"},{"groupId":"OG002","value":"313"},{"groupId":"OG003","value":"325"},{"groupId":"OG004","value":"306"},{"groupId":"OG005","value":"344"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Significant Laboratory Abnormalities - Liver","description":"The number of treated participants who experienced a laboratory abnormality of the liver during the course of the study.\n\nAspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN) Results reported in International System of Units (SI)","populationDescription":"All treated participants with at least one clinically significant liver laboratory abnormality","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to up to approximately 38 months","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"642"},{"groupId":"OG001","value":"303"},{"groupId":"OG002","value":"280"},{"groupId":"OG003","value":"306"},{"groupId":"OG004","value":"281"},{"groupId":"OG005","value":"324"},{"groupId":"OG006","value":"21"},{"groupId":"OG007","value":"16"}]}],"classes":[{"title":"ALT > 3x ULN","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"642"},{"groupId":"OG001","value":"303"},{"groupId":"OG002","value":"280"},{"groupId":"OG003","value":"306"},{"groupId":"OG004","value":"280"},{"groupId":"OG005","value":"324"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"ALT > 5x ULN","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"642"},{"groupId":"OG001","value":"303"},{"groupId":"OG002","value":"280"},{"groupId":"OG003","value":"306"},{"groupId":"OG004","value":"280"},{"groupId":"OG005","value":"324"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"ALT > 10x ULN","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"642"},{"groupId":"OG001","value":"303"},{"groupId":"OG002","value":"280"},{"groupId":"OG003","value":"306"},{"groupId":"OG004","value":"280"},{"groupId":"OG005","value":"324"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"ALT > 20x ULN","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"642"},{"groupId":"OG001","value":"303"},{"groupId":"OG002","value":"280"},{"groupId":"OG003","value":"306"},{"groupId":"OG004","value":"280"},{"groupId":"OG005","value":"324"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"AST > 3x ULN","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"641"},{"groupId":"OG001","value":"302"},{"groupId":"OG002","value":"280"},{"groupId":"OG003","value":"304"},{"groupId":"OG004","value":"281"},{"groupId":"OG005","value":"323"},{"groupId":"OG006","value":"21"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"}]}]},{"title":"AST > 5x ULN","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"641"},{"groupId":"OG001","value":"302"},{"groupId":"OG002","value":"280"},{"groupId":"OG003","value":"304"},{"groupId":"OG004","value":"281"},{"groupId":"OG005","value":"323"},{"groupId":"OG006","value":"21"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"}]}]},{"title":"AST > 10x ULN","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"641"},{"groupId":"OG001","value":"302"},{"groupId":"OG002","value":"280"},{"groupId":"OG003","value":"304"},{"groupId":"OG004","value":"281"},{"groupId":"OG005","value":"323"},{"groupId":"OG006","value":"21"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"AST > 20x ULN","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"641"},{"groupId":"OG001","value":"302"},{"groupId":"OG002","value":"280"},{"groupId":"OG003","value":"304"},{"groupId":"OG004","value":"281"},{"groupId":"OG005","value":"323"},{"groupId":"OG006","value":"21"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"ALP > 2x ULN","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"640"},{"groupId":"OG001","value":"300"},{"groupId":"OG002","value":"276"},{"groupId":"OG003","value":"305"},{"groupId":"OG004","value":"279"},{"groupId":"OG005","value":"319"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"Total Bilirubin > 1.5x ULN","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"639"},{"groupId":"OG001","value":"302"},{"groupId":"OG002","value":"277"},{"groupId":"OG003","value":"304"},{"groupId":"OG004","value":"279"},{"groupId":"OG005","value":"318"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"Total Bilirubin > 2x ULN","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"639"},{"groupId":"OG001","value":"302"},{"groupId":"OG002","value":"277"},{"groupId":"OG003","value":"304"},{"groupId":"OG004","value":"279"},{"groupId":"OG005","value":"318"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"Concurrent ALT/AST Elevation > 3x ULN with total bilirubin >2x ULN","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"639"},{"groupId":"OG001","value":"302"},{"groupId":"OG002","value":"277"},{"groupId":"OG003","value":"304"},{"groupId":"OG004","value":"279"},{"groupId":"OG005","value":"318"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in aPTT Activity","description":"Percent change from baseline in activated partial thromboplastin time (aPTT) activity via exposure response.","populationDescription":"All participants with at least one aPTT pharmacodynamic endpoint assessed after first dose","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percent change","timeFrame":"Baseline and day 90","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"503"},{"groupId":"OG001","value":"251"},{"groupId":"OG002","value":"226"},{"groupId":"OG003","value":"241"},{"groupId":"OG004","value":"214"},{"groupId":"OG005","value":"232"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"14"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.47","spread":"0.768"},{"groupId":"OG001","value":"38.72","spread":"2.264"},{"groupId":"OG002","value":"58.30","spread":"3.195"},{"groupId":"OG003","value":"97.32","spread":"3.601"},{"groupId":"OG004","value":"140.76","spread":"5.154"},{"groupId":"OG005","value":"193.64","spread":"7.041"},{"groupId":"OG006","value":"48.48","spread":"11.243"},{"groupId":"OG007","value":"118.06","spread":"13.840"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Factor XI Clotting Activity","description":"Percent change from baseline in factor XI clotting activity via exposure response.","populationDescription":"All participants with at least one factor XI clotting pharmacodynamic endpoint assessed after first dose","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percent change","timeFrame":"Baseline and day 90","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"503"},{"groupId":"OG001","value":"251"},{"groupId":"OG002","value":"223"},{"groupId":"OG003","value":"228"},{"groupId":"OG004","value":"216"},{"groupId":"OG005","value":"236"},{"groupId":"OG006","value":"15"},{"groupId":"OG007","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.48","spread":"3.455"},{"groupId":"OG001","value":"-8.88","spread":"1.280"},{"groupId":"OG002","value":"-17.67","spread":"1.900"},{"groupId":"OG003","value":"-37.20","spread":"1.655"},{"groupId":"OG004","value":"-61.52","spread":"1.869"},{"groupId":"OG005","value":"-70.25","spread":"3.043"},{"groupId":"OG006","value":"3.86","spread":"13.754"},{"groupId":"OG007","value":"-44.27","spread":"6.501"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Parameter - Estimated Clearance (CL)","description":"Pharmacokinetic Parameter - Estimated Clearance (CL). CL is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.","populationDescription":"All treated participants with at least one post-dose PK sample. Pre-specified for data to be collected only in the 25 mg QD, and BID dose regimens.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"L/h","timeFrame":"From first dose to up to 90 days after first dose","groups":[{"id":"OG000","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"323"},{"groupId":"OG001","value":"307"},{"groupId":"OG002","value":"323"},{"groupId":"OG003","value":"303"},{"groupId":"OG004","value":"341"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.15","spread":"34"},{"groupId":"OG001","value":"8.01","spread":"34.3"},{"groupId":"OG002","value":"7.54","spread":"32.8"},{"groupId":"OG003","value":"7.08","spread":"31.3"},{"groupId":"OG004","value":"7.43","spread":"32.9"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Parameter - Volume of the Central Compartment (VC)","description":"Pharmacokinetic Parameter - Volume of the Central Compartment (VC). VC is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.","populationDescription":"All treated participants with at least one post-dose PK sample. Pre-specified for data to be collected only in the 25 mg QD, and BID dose regimens.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"L","timeFrame":"From first dose to up to 90 days after first dose","groups":[{"id":"OG000","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"323"},{"groupId":"OG001","value":"307"},{"groupId":"OG002","value":"323"},{"groupId":"OG003","value":"303"},{"groupId":"OG004","value":"341"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.9","spread":"152"},{"groupId":"OG001","value":"31.4","spread":"138"},{"groupId":"OG002","value":"30.9","spread":"145"},{"groupId":"OG003","value":"28.9","spread":"149"},{"groupId":"OG004","value":"31.6","spread":"181"}]}]}]},{"type":"SECONDARY","title":"Volume of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI","description":"Total volume of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.","populationDescription":"All randomized participants with an evaluable MRI","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mL","timeFrame":"At day 90","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"49"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"35"},{"groupId":"OG005","value":"35"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3492","spread":"11.40906"},{"groupId":"OG001","value":"0.8976","spread":"1.96342"},{"groupId":"OG002","value":"2.9902","spread":"8.28993"},{"groupId":"OG003","value":"1.2682","spread":"2.72452"},{"groupId":"OG004","value":"1.4727","spread":"3.78795"},{"groupId":"OG005","value":"1.2711","spread":"4.05035"},{"groupId":"OG006","value":"8.8960","spread":"13.85294"},{"groupId":"OG007","value":"1.4503","spread":"1.89112"}]}]}]},{"type":"SECONDARY","title":"Number of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI","description":"Number of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.","populationDescription":"All randomized participants with an evaluable MRI","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At day 90","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"49"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"35"},{"groupId":"OG005","value":"35"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"}]}],"classes":[{"title":">0","categories":[{"measurements":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"49"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"35"},{"groupId":"OG005","value":"35"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"}]}]},{"title":"1","categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"23"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"2"}]}]},{"title":"2","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"}]}]},{"title":"3","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"4","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"}]}]},{"title":"5","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":">5","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent of Participants With Ischemic Stroke Events","description":"Secondary analysis of symptomatic ischemic stroke events. Clinical events are included up to day 90. Wald 95% CI within group. Undetermined stroke is included.","populationDescription":"All randomized participants","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From randomization to up to 90 days after randomization","groups":[{"id":"OG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG002","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG003","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG004","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG005","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG006","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."},{"id":"OG007","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"691"},{"groupId":"OG001","value":"328"},{"groupId":"OG002","value":"318"},{"groupId":"OG003","value":"328"},{"groupId":"OG004","value":"310"},{"groupId":"OG005","value":"351"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"18"}]}],"classes":[{"title":"Ischemic stroke","categories":[{"measurements":[{"groupId":"OG000","value":"5.5","lowerLimit":"3.8","upperLimit":"7.2"},{"groupId":"OG001","value":"4.6","lowerLimit":"2.3","upperLimit":"6.8"},{"groupId":"OG002","value":"3.8","lowerLimit":"1.7","upperLimit":"5.9"},{"groupId":"OG003","value":"4.0","lowerLimit":"1.9","upperLimit":"6.1"},{"groupId":"OG004","value":"3.5","lowerLimit":"1.5","upperLimit":"5.6"},{"groupId":"OG005","value":"7.7","lowerLimit":"4.9","upperLimit":"10.5"},{"groupId":"OG006","value":"13.6","lowerLimit":"0.0","upperLimit":"28.0"},{"groupId":"OG007","value":"5.6","lowerLimit":"0.0","upperLimit":"16.1"}]}]},{"title":"Undetermined stroke","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG004","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG005","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG006","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG007","value":"0","lowerLimit":"0","upperLimit":"0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Milvexian 25 mg QD over Placebo","nonInferiorityType":"SUPERIORITY","statisticalMethod":"Wald Confidence Limits","statisticalComment":"95% CIs for RR are constructed using Wald Confidence Limits","paramType":"Relative Risk (RR)","paramValue":"0.83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.46","ciUpperLimit":"1.49"},{"groupIds":["OG000","OG002"],"groupDescription":"Milvexian 25 mg BID over Placebo","nonInferiorityType":"SUPERIORITY","statisticalMethod":"Wald Confidence Limits","statisticalComment":"95% CIs for RR are constructed using Wald Confidence Limits","paramType":"Relative Risk (RR)","paramValue":"0.69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.36","ciUpperLimit":"1.30"},{"groupIds":["OG000","OG003"],"groupDescription":"Milvexian 50 mg BID over Placebo","nonInferiorityType":"SUPERIORITY","statisticalMethod":"Wald Confidence Limits","statisticalComment":"95% CIs for RR are constructed using Wald Confidence Limits","paramType":"Relative Risk (RR)","paramValue":"0.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.39","ciUpperLimit":"1.33"},{"groupIds":["OG000","OG004"],"groupDescription":"Milvexian 100 mg BID over Placebo","nonInferiorityType":"SUPERIORITY","statisticalMethod":"Wald Confidence Limits","statisticalComment":"95% CIs for RR are constructed using Wald Confidence Limits","paramType":"Relative Risk (RR)","paramValue":"0.65","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.33","ciUpperLimit":"1.25"},{"groupIds":["OG000","OG005"],"groupDescription":"Milvexian 200 mg BID","nonInferiorityType":"SUPERIORITY","statisticalMethod":"Wald Confidence Limits","statisticalComment":"95% CIs for RR are constructed using Wald Confidence Limits","paramType":"Relative Risk (RR)","paramValue":"1.40","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.87","ciUpperLimit":"2.25"},{"groupIds":["OG000","OG006"],"groupDescription":"Milvexian 50 mg QD over Placebo","nonInferiorityType":"SUPERIORITY","statisticalMethod":"Wald Confidence Limits","statisticalComment":"95% CIs for RR are constructed using Wald Confidence Limits","paramType":"Relative Risk (RR)","paramValue":"2.48","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.83","ciUpperLimit":"7.42"},{"groupIds":["OG000","OG007"],"groupDescription":"Milvexian 100 mg QD over Placebo","nonInferiorityType":"SUPERIORITY","statisticalMethod":"Wald Confidence Limits","statisticalComment":"95% CIs for RR are constructed using Wald Confidence Limits","paramType":"Relative Risk (RR)","paramValue":"1.01","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.15","ciUpperLimit":"6.96"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Participants were assessed for all-cause mortality from their randomization until their study completion (up to approximately 38 months). SAEs and Other AEs were assessed from first dose to 7 days after last dose of study therapy (up to approximately 112 days).","description":"The total number at risk for all-cause mortality represents all participants who were randomized. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants who received at least 1 dose of study medication.","eventGroups":[{"id":"EG000","title":"Placebo","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.","deathsNumAffected":5,"deathsNumAtRisk":691,"seriousNumAffected":94,"seriousNumAtRisk":682,"otherNumAffected":178,"otherNumAtRisk":682},{"id":"EG001","title":"Milvexian 25 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.","deathsNumAffected":4,"deathsNumAtRisk":328,"seriousNumAffected":37,"seriousNumAtRisk":325,"otherNumAffected":81,"otherNumAtRisk":325},{"id":"EG002","title":"Milvexian 50 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.","deathsNumAffected":0,"deathsNumAtRisk":22,"seriousNumAffected":5,"seriousNumAtRisk":22,"otherNumAffected":6,"otherNumAtRisk":22},{"id":"EG003","title":"Milvexian 100 mg QD","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.","deathsNumAffected":0,"deathsNumAtRisk":18,"seriousNumAffected":3,"seriousNumAtRisk":17,"otherNumAffected":11,"otherNumAtRisk":17},{"id":"EG004","title":"Milvexian 25 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.","deathsNumAffected":3,"deathsNumAtRisk":318,"seriousNumAffected":39,"seriousNumAtRisk":313,"otherNumAffected":83,"otherNumAtRisk":313},{"id":"EG005","title":"Milvexian 50 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.","deathsNumAffected":3,"deathsNumAtRisk":328,"seriousNumAffected":41,"seriousNumAtRisk":325,"otherNumAffected":92,"otherNumAtRisk":325},{"id":"EG006","title":"Milvexian 100 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.","deathsNumAffected":5,"deathsNumAtRisk":310,"seriousNumAffected":42,"seriousNumAtRisk":306,"otherNumAffected":82,"otherNumAtRisk":306},{"id":"EG007","title":"Milvexian 200 mg BID","description":"Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.","deathsNumAffected":5,"deathsNumAtRisk":351,"seriousNumAffected":54,"seriousNumAtRisk":344,"otherNumAffected":90,"otherNumAtRisk":344}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":1,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":682},{"groupId":"EG001","numAffected":3,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":3,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Atrial tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Atrioventricular block complete","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Atrioventricular block second degree","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":2,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Cardiac failure acute","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Cardiac ventricular thrombosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Intracardiac thrombus","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Ischaemic cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":2,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Nodal rhythm","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Prinzmetal angina","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Atrial septal defect","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":2,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Vertigo positional","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Retinal detachment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Diverticulum intestinal haemorrhagic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Duodenal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Duodenal ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Duodenal ulcer perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Faecaloma","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Gastric ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":2,"numAtRisk":344}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Haemorrhoidal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Mallory-Weiss syndrome","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Oesophagitis haemorrhagic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Peptic ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Small intestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Sudden cardiac death","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Hepatitis fulminant","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Arthritis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":682},{"groupId":"EG001","numAffected":2,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":2,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":2,"numAtRisk":344}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Clostridium difficile infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Diverticulitis intestinal perforated","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Febrile infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Infected dermal cyst","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Large intestine infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":1,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":2,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Pneumonia aspiration","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Staphylococcal bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":2,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":5,"numAtRisk":344}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Wound infection pseudomonas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Accidental overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Cystitis radiation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Fibula fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Forearm fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Post procedural haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Post procedural stroke","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Procedural haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Radius fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Reactive gastropathy","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Activated partial thromboplastin time prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Ejection fraction decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Liver function test increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Type 2 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"B-cell lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Colon cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Intestinal adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Invasive ductal breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Metastases to lung","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Metastatic neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Sinonasal papilloma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Squamous cell carcinoma of lung","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Aphasia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Basilar artery occlusion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Basilar artery stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Basilar migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Brain stem stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Carotid artery stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Carotid artery thrombosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":2,"numAtRisk":344}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Cerebral venous thrombosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Dementia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Dysarthria","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Embolic cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Focal dyscognitive seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Generalised tonic-clonic seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Haemorrhagic transformation stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":2,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Intracranial aneurysm","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Ischaemic cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":3,"numAtRisk":313},{"groupId":"EG005","numAffected":2,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":3,"numAtRisk":344}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":682},{"groupId":"EG001","numAffected":9,"numAtRisk":325},{"groupId":"EG002","numAffected":3,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":6,"numAtRisk":313},{"groupId":"EG005","numAffected":10,"numAtRisk":325},{"groupId":"EG006","numAffected":7,"numAtRisk":306},{"groupId":"EG007","numAffected":11,"numAtRisk":344}]},{"term":"Lacunar stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Mental impairment","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Myasthenia gravis crisis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Myelopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Neurological symptom","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Peroneal nerve palsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Pseudostroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Sedation complication","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Stroke in evolution","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":682},{"groupId":"EG001","numAffected":2,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":4,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":8,"numAtRisk":344}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Toxic encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":4,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":4,"numAtRisk":306},{"groupId":"EG007","numAffected":4,"numAtRisk":344}]},{"term":"Vertebral artery dissection","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Anxiety disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Mania","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":4,"numAtRisk":344}]},{"term":"Cystitis haemorrhagic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Nephropathy toxic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":2,"numAtRisk":344}]},{"term":"Prerenal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":2,"numAtRisk":344}]},{"term":"Renal tubular necrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Benign prostatic hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Diabetic foot","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":2,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Drug eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Rash macular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Toxic epidermal necrolysis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":1,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Malignant hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Peripheral arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Peripheral artery thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":2,"numAtRisk":17},{"groupId":"EG004","numAffected":2,"numAtRisk":313},{"groupId":"EG005","numAffected":2,"numAtRisk":325},{"groupId":"EG006","numAffected":5,"numAtRisk":306},{"groupId":"EG007","numAffected":8,"numAtRisk":344}]},{"term":"Increased tendency to bruise","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Iron deficiency anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":2,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":682},{"groupId":"EG001","numAffected":3,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":2,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":44,"numAtRisk":682},{"groupId":"EG001","numAffected":22,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":3,"numAtRisk":17},{"groupId":"EG004","numAffected":17,"numAtRisk":313},{"groupId":"EG005","numAffected":20,"numAtRisk":325},{"groupId":"EG006","numAffected":20,"numAtRisk":306},{"groupId":"EG007","numAffected":24,"numAtRisk":344}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":2,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Gingival bleeding","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":682},{"groupId":"EG001","numAffected":11,"numAtRisk":325},{"groupId":"EG002","numAffected":1,"numAtRisk":22},{"groupId":"EG003","numAffected":2,"numAtRisk":17},{"groupId":"EG004","numAffected":6,"numAtRisk":313},{"groupId":"EG005","numAffected":6,"numAtRisk":325},{"groupId":"EG006","numAffected":11,"numAtRisk":306},{"groupId":"EG007","numAffected":5,"numAtRisk":344}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":2,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":2,"numAtRisk":344}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":682},{"groupId":"EG001","numAffected":7,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":2,"numAtRisk":313},{"groupId":"EG005","numAffected":3,"numAtRisk":325},{"groupId":"EG006","numAffected":3,"numAtRisk":306},{"groupId":"EG007","numAffected":3,"numAtRisk":344}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":682},{"groupId":"EG001","numAffected":2,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":2,"numAtRisk":17},{"groupId":"EG004","numAffected":3,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":2,"numAtRisk":306},{"groupId":"EG007","numAffected":4,"numAtRisk":344}]},{"term":"Feeling cold","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":2,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Thirst","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":682},{"groupId":"EG001","numAffected":8,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":9,"numAtRisk":313},{"groupId":"EG005","numAffected":6,"numAtRisk":325},{"groupId":"EG006","numAffected":11,"numAtRisk":306},{"groupId":"EG007","numAffected":12,"numAtRisk":344}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Skin abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":2,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":3,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Activated partial thromboplastin time prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":682},{"groupId":"EG001","numAffected":2,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":2,"numAtRisk":325},{"groupId":"EG006","numAffected":3,"numAtRisk":306},{"groupId":"EG007","numAffected":3,"numAtRisk":344}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":2,"numAtRisk":344}]},{"term":"Melanocytic naevus","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":682},{"groupId":"EG001","numAffected":4,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":4,"numAtRisk":313},{"groupId":"EG005","numAffected":7,"numAtRisk":325},{"groupId":"EG006","numAffected":5,"numAtRisk":306},{"groupId":"EG007","numAffected":2,"numAtRisk":344}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":682},{"groupId":"EG001","numAffected":16,"numAtRisk":325},{"groupId":"EG002","numAffected":3,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":12,"numAtRisk":313},{"groupId":"EG005","numAffected":14,"numAtRisk":325},{"groupId":"EG006","numAffected":12,"numAtRisk":306},{"groupId":"EG007","numAffected":9,"numAtRisk":344}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":1,"numAtRisk":22},{"groupId":"EG003","numAffected":2,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":3,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":682},{"groupId":"EG001","numAffected":3,"numAtRisk":325},{"groupId":"EG002","numAffected":1,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":6,"numAtRisk":313},{"groupId":"EG005","numAffected":3,"numAtRisk":325},{"groupId":"EG006","numAffected":5,"numAtRisk":306},{"groupId":"EG007","numAffected":3,"numAtRisk":344}]},{"term":"Depressed mood","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":2,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Disorientation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":682},{"groupId":"EG001","numAffected":0,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":2,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":9,"numAtRisk":344}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":325},{"groupId":"EG006","numAffected":2,"numAtRisk":306},{"groupId":"EG007","numAffected":1,"numAtRisk":344}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":682},{"groupId":"EG001","numAffected":2,"numAtRisk":325},{"groupId":"EG002","numAffected":2,"numAtRisk":22},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":4,"numAtRisk":313},{"groupId":"EG005","numAffected":5,"numAtRisk":325},{"groupId":"EG006","numAffected":4,"numAtRisk":306},{"groupId":"EG007","numAffected":6,"numAtRisk":344}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":682},{"groupId":"EG001","numAffected":1,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":2,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":325},{"groupId":"EG006","numAffected":0,"numAtRisk":306},{"groupId":"EG007","numAffected":0,"numAtRisk":344}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":56,"numAtRisk":682},{"groupId":"EG001","numAffected":21,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":2,"numAtRisk":17},{"groupId":"EG004","numAffected":23,"numAtRisk":313},{"groupId":"EG005","numAffected":24,"numAtRisk":325},{"groupId":"EG006","numAffected":20,"numAtRisk":306},{"groupId":"EG007","numAffected":19,"numAtRisk":344}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":682},{"groupId":"EG001","numAffected":2,"numAtRisk":325},{"groupId":"EG002","numAffected":0,"numAtRisk":22},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":2,"numAtRisk":313},{"groupId":"EG005","numAffected":4,"numAtRisk":325},{"groupId":"EG006","numAffected":1,"numAtRisk":306},{"groupId":"EG007","numAffected":3,"numAtRisk":344}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."},"pointOfContact":{"title":"Bristol-Myers Squibb Study Director","organization":"Bristol-Myers Squibb","email":"Clinical.Trials@bms.com","phone":"Please email"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2020-10-09","uploadDate":"2023-03-31T19:09","filename":"Prot_SAP_000.pdf","size":11180398}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2023-04-21","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002546","term":"Ischemic Attack, Transient"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000002545","term":"Brain Ischemia"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5485","name":"Ischemic Attack, Transient","asFound":"Transient Ischemic Attack (TIA)","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001241","term":"Aspirin"},{"id":"D000077144","term":"Clopidogrel"}],"ancestors":[{"id":"D000000894","term":"Anti-Inflammatory Agents, Non-Steroidal"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000893","term":"Anti-Inflammatory Agents"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000016861","term":"Cyclooxygenase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000058633","term":"Antipyretics"},{"id":"D000058921","term":"Purinergic P2Y Receptor Antagonists"},{"id":"D000058919","term":"Purinergic P2 Receptor Antagonists"},{"id":"D000058914","term":"Purinergic Antagonists"},{"id":"D000058905","term":"Purinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","asFound":"Knee","relevance":"HIGH"},{"id":"M1669","name":"Clopidogrel","asFound":"Results","relevance":"HIGH"},{"id":"M3907","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M3908","name":"Anti-Inflammatory Agents, Non-Steroidal","relevance":"LOW"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M20476","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20294","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M18899","name":"Cyclooxygenase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M28866","name":"Antipyretics","relevance":"LOW"},{"id":"M28984","name":"Purinergic P2Y Receptor Antagonists","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}